{"idB": "1006281_18_item1_p147_s2", "idA": "1006281_17_item1_p138_s1", "sentA": "Assuming that the clinical data support the product s safety and effectiveness for its intended use, a new drug application, or NDA, or a BLA is submitted to the FDA for review.", "sentB": "BLA or NDA review usually does not begin until the drug company has submitted the entire application to the FDA.", "type": 1, "words": ["<tag1>", "Assuming", "that", "the", "clinical", "data", "support", "the", "product", "s", "safety", "and", "effectiveness", "for", "its", "intended", "use,", "a", "new", "drug", "application,", "or", "NDA,", "or", "a", "BLA", "is", "submitted", "to", "the", "FDA", "for", "review.", "<tag2>", "BLA", "or", "NDA", "review", "usually", "does", "not", "begin", "until", "the", "drug", "company", "has", "submitted", "the", "entire", "application", "to", "the", "FDA.", "<tag3>"], "wordsA": ["Assuming", "that", "the", "clinical", "data", "support", "the", "product", "s", "safety", "and", "effectiveness", "for", "its", "intended", "use,", "a", "new", "drug", "application,", "or", "NDA,", "or", "a", "BLA", "is", "submitted", "to", "the", "FDA", "for", "review."], "wordsB": ["BLA", "or", "NDA", "review", "usually", "does", "not", "begin", "until", "the", "drug", "company", "has", "submitted", "the", "entire", "application", "to", "the", "FDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_18_item1_p55_s1", "idA": "1006281_17_item1_p139_s0", "sentA": "Under the Orphan Drug Act of 1983, the FDA may grant orphan drug designation to drugs and biological products intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States.", "sentB": "It is a disease or condition associated with morbidity that has a substantial impact on survival, day-to-day function, and the likelihood that the disease, if left untreated, will progress from a less severe condition to a more serious one.", "type": 1, "words": ["<tag1>", "Under", "the", "Orphan", "Drug", "Act", "of", "1983,", "the", "FDA", "may", "grant", "orphan", "drug", "designation", "to", "drugs", "and", "biological", "products", "intended", "to", "treat", "a", "rare", "disease", "or", "condition,", "which", "is", "generally", "a", "disease", "or", "condition", "that", "affects", "fewer", "than", "200,000", "individuals", "in", "the", "United", "States.", "<tag2>", "It", "is", "a", "disease", "or", "condition", "associated", "with", "morbidity", "that", "has", "a", "substantial", "impact", "on", "survival,", "day-to-day", "function,", "and", "the", "likelihood", "that", "the", "disease,", "if", "left", "untreated,", "will", "progress", "from", "a", "less", "severe", "condition", "to", "a", "more", "serious", "one.", "<tag3>"], "wordsA": ["Under", "the", "Orphan", "Drug", "Act", "of", "1983,", "the", "FDA", "may", "grant", "orphan", "drug", "designation", "to", "drugs", "and", "biological", "products", "intended", "to", "treat", "a", "rare", "disease", "or", "condition,", "which", "is", "generally", "a", "disease", "or", "condition", "that", "affects", "fewer", "than", "200,000", "individuals", "in", "the", "United", "States."], "wordsB": ["It", "is", "a", "disease", "or", "condition", "associated", "with", "morbidity", "that", "has", "a", "substantial", "impact", "on", "survival,", "day-to-day", "function,", "and", "the", "likelihood", "that", "the", "disease,", "if", "left", "untreated,", "will", "progress", "from", "a", "less", "severe", "condition", "to", "a", "more", "serious", "one."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_18_item1_p147_s1", "idA": "1006281_17_item1_p142_s1", "sentA": "For a fast track product, the FDA may consider for review on a rolling basis sections of the NDA or BLA before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA or BLA as they become available and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA or BLA.", "sentB": "A drug candidate that receives Fast Track designation from the FDA is eligible for some or all of the following: more frequent meetings with the FDA to discuss the drug s development plan and ensure collection of appropriate data needed to support drug approval; more frequent written communication from the FDA about such things as the design of the proposed clinical trials; eligibility for the FDA s Accelerated Approval and Priority Review, if relevant criteria are met; and eligibility for Rolling Review, which allows a drug company to submit completed sections of its BLA or NDA for review by the FDA, rather than waiting until every section of the BLA or NDA is completed before the entire application can be reviewed.", "type": 1, "words": ["<tag1>", "For", "a", "fast", "track", "product,", "the", "FDA", "may", "consider", "for", "review", "on", "a", "rolling", "basis", "sections", "of", "the", "NDA", "or", "BLA", "before", "the", "complete", "application", "is", "submitted,", "if", "the", "sponsor", "provides", "a", "schedule", "for", "the", "submission", "of", "the", "sections", "of", "the", "NDA,", "the", "FDA", "agrees", "to", "accept", "sections", "of", "the", "NDA", "or", "BLA", "as", "they", "become", "available", "and", "determines", "that", "the", "schedule", "is", "acceptable,", "and", "the", "sponsor", "pays", "any", "required", "user", "fees", "upon", "submission", "of", "the", "first", "section", "of", "the", "NDA", "or", "BLA.", "<tag2>", "A", "drug", "candidate", "that", "receives", "Fast", "Track", "designation", "from", "the", "FDA", "is", "eligible", "for", "some", "or", "all", "of", "the", "following:", "more", "frequent", "meetings", "with", "the", "FDA", "to", "discuss", "the", "drug", "s", "development", "plan", "and", "ensure", "collection", "of", "appropriate", "data", "needed", "to", "support", "drug", "approval;", "more", "frequent", "written", "communication", "from", "the", "FDA", "about", "such", "things", "as", "the", "design", "of", "the", "proposed", "clinical", "trials;", "eligibility", "for", "the", "FDA", "s", "Accelerated", "Approval", "and", "Priority", "Review,", "if", "relevant", "criteria", "are", "met;", "and", "eligibility", "for", "Rolling", "Review,", "which", "allows", "a", "drug", "company", "to", "submit", "completed", "sections", "of", "its", "BLA", "or", "NDA", "for", "review", "by", "the", "FDA,", "rather", "than", "waiting", "until", "every", "section", "of", "the", "BLA", "or", "NDA", "is", "completed", "before", "the", "entire", "application", "can", "be", "reviewed.", "<tag3>"], "wordsA": ["For", "a", "fast", "track", "product,", "the", "FDA", "may", "consider", "for", "review", "on", "a", "rolling", "basis", "sections", "of", "the", "NDA", "or", "BLA", "before", "the", "complete", "application", "is", "submitted,", "if", "the", "sponsor", "provides", "a", "schedule", "for", "the", "submission", "of", "the", "sections", "of", "the", "NDA,", "the", "FDA", "agrees", "to", "accept", "sections", "of", "the", "NDA", "or", "BLA", "as", "they", "become", "available", "and", "determines", "that", "the", "schedule", "is", "acceptable,", "and", "the", "sponsor", "pays", "any", "required", "user", "fees", "upon", "submission", "of", "the", "first", "section", "of", "the", "NDA", "or", "BLA."], "wordsB": ["A", "drug", "candidate", "that", "receives", "Fast", "Track", "designation", "from", "the", "FDA", "is", "eligible", "for", "some", "or", "all", "of", "the", "following:", "more", "frequent", "meetings", "with", "the", "FDA", "to", "discuss", "the", "drug", "s", "development", "plan", "and", "ensure", "collection", "of", "appropriate", "data", "needed", "to", "support", "drug", "approval;", "more", "frequent", "written", "communication", "from", "the", "FDA", "about", "such", "things", "as", "the", "design", "of", "the", "proposed", "clinical", "trials;", "eligibility", "for", "the", "FDA", "s", "Accelerated", "Approval", "and", "Priority", "Review,", "if", "relevant", "criteria", "are", "met;", "and", "eligibility", "for", "Rolling", "Review,", "which", "allows", "a", "drug", "company", "to", "submit", "completed", "sections", "of", "its", "BLA", "or", "NDA", "for", "review", "by", "the", "FDA,", "rather", "than", "waiting", "until", "every", "section", "of", "the", "BLA", "or", "NDA", "is", "completed", "before", "the", "entire", "application", "can", "be", "reviewed."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_18_item1_p4_s2", "idA": "1006281_17_item1_p24_s3", "sentA": "We also believe that the significant benefits of our ProCellEx system, if further substantiated in clinical trials and in the successful commercialization of taliglucerase alfa and our other product candidates, have the potential to transform the industry standard for the development of complex therapeutic proteins.", "sentB": "The COMP cited clinical and non-clinical justifications we provided to establish the significant benefit of pegunigalsidase alfa, noting that the COMP considered the justifications to constitute a clinically relevant advantage.", "type": 1, "words": ["<tag1>", "We", "also", "believe", "that", "the", "significant", "benefits", "of", "our", "ProCellEx", "system,", "if", "further", "substantiated", "in", "clinical", "trials", "and", "in", "the", "successful", "commercialization", "of", "taliglucerase", "alfa", "and", "our", "other", "product", "candidates,", "have", "the", "potential", "to", "transform", "the", "industry", "standard", "for", "the", "development", "of", "complex", "therapeutic", "proteins.", "<tag2>", "The", "COMP", "cited", "clinical", "and", "non-clinical", "justifications", "we", "provided", "to", "establish", "the", "significant", "benefit", "of", "pegunigalsidase", "alfa,", "noting", "that", "the", "COMP", "considered", "the", "justifications", "to", "constitute", "a", "clinically", "relevant", "advantage.", "<tag3>"], "wordsA": ["We", "also", "believe", "that", "the", "significant", "benefits", "of", "our", "ProCellEx", "system,", "if", "further", "substantiated", "in", "clinical", "trials", "and", "in", "the", "successful", "commercialization", "of", "taliglucerase", "alfa", "and", "our", "other", "product", "candidates,", "have", "the", "potential", "to", "transform", "the", "industry", "standard", "for", "the", "development", "of", "complex", "therapeutic", "proteins."], "wordsB": ["The", "COMP", "cited", "clinical", "and", "non-clinical", "justifications", "we", "provided", "to", "establish", "the", "significant", "benefit", "of", "pegunigalsidase", "alfa,", "noting", "that", "the", "COMP", "considered", "the", "justifications", "to", "constitute", "a", "clinically", "relevant", "advantage."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_18_item1_p127_s0", "idA": "1006281_17_item1_p41_s3", "sentA": "In August 2014, the FDA approved Elelyso for injection for pediatric patients, and other jurisdictions, including Brazil, approved pediatric indications thereafter.", "sentB": "In 2017, the FDA approved the Supplemental New Drug Application (sNDA) we submitted to allow us to convert our manufacturing facility from a single dedicated product facility to a multi-product facility.", "type": 1, "words": ["<tag1>", "In", "August", "2014,", "the", "FDA", "approved", "Elelyso", "for", "injection", "for", "pediatric", "patients,", "and", "other", "jurisdictions,", "including", "Brazil,", "approved", "pediatric", "indications", "thereafter.", "<tag2>", "In", "2017,", "the", "FDA", "approved", "the", "Supplemental", "New", "Drug", "Application", "(sNDA)", "we", "submitted", "to", "allow", "us", "to", "convert", "our", "manufacturing", "facility", "from", "a", "single", "dedicated", "product", "facility", "to", "a", "multi-product", "facility.", "<tag3>"], "wordsA": ["In", "August", "2014,", "the", "FDA", "approved", "Elelyso", "for", "injection", "for", "pediatric", "patients,", "and", "other", "jurisdictions,", "including", "Brazil,", "approved", "pediatric", "indications", "thereafter."], "wordsB": ["In", "2017,", "the", "FDA", "approved", "the", "Supplemental", "New", "Drug", "Application", "(sNDA)", "we", "submitted", "to", "allow", "us", "to", "convert", "our", "manufacturing", "facility", "from", "a", "single", "dedicated", "product", "facility", "to", "a", "multi-product", "facility."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_18_item1_p5_s2", "idA": "1006281_17_item1_p50_s0", "sentA": "We believe that the treatment of Fabry disease is a specialty clinical niche with the potential for high growth as there is a significant unmet medical need for Fabry disease treatments.", "sentB": "The market exclusivity will not have any effect on Fabry disease treatments already approved at that time.", "type": 1, "words": ["<tag1>", "We", "believe", "that", "the", "treatment", "of", "Fabry", "disease", "is", "a", "specialty", "clinical", "niche", "with", "the", "potential", "for", "high", "growth", "as", "there", "is", "a", "significant", "unmet", "medical", "need", "for", "Fabry", "disease", "treatments.", "<tag2>", "The", "market", "exclusivity", "will", "not", "have", "any", "effect", "on", "Fabry", "disease", "treatments", "already", "approved", "at", "that", "time.", "<tag3>"], "wordsA": ["We", "believe", "that", "the", "treatment", "of", "Fabry", "disease", "is", "a", "specialty", "clinical", "niche", "with", "the", "potential", "for", "high", "growth", "as", "there", "is", "a", "significant", "unmet", "medical", "need", "for", "Fabry", "disease", "treatments."], "wordsB": ["The", "market", "exclusivity", "will", "not", "have", "any", "effect", "on", "Fabry", "disease", "treatments", "already", "approved", "at", "that", "time."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_18_item1_p56_s1", "idA": "1006281_17_item1_p53_s0", "sentA": "In PRX-102, the prh-alpha-GALA, naturally occurring as a homodimer, is PEGylated and cross-linked to support and reinforce the homodimeric structure, which is crucial for the enzymatic activity of this enzyme.", "sentB": "The absence or reduction of this enzymatic activity leads to the progressive accumulation of glycolipids, especially Gb3, in capillary endothelial cells, podocytes, tubular cells, glomerular endothelial cells, mesangial cells, interstitial cells, cardiomyocytes, fibroblasts, and neurons.", "type": 1, "words": ["<tag1>", "In", "PRX-102,", "the", "prh-alpha-GALA,", "naturally", "occurring", "as", "a", "homodimer,", "is", "PEGylated", "and", "cross-linked", "to", "support", "and", "reinforce", "the", "homodimeric", "structure,", "which", "is", "crucial", "for", "the", "enzymatic", "activity", "of", "this", "enzyme.", "<tag2>", "The", "absence", "or", "reduction", "of", "this", "enzymatic", "activity", "leads", "to", "the", "progressive", "accumulation", "of", "glycolipids,", "especially", "Gb3,", "in", "capillary", "endothelial", "cells,", "podocytes,", "tubular", "cells,", "glomerular", "endothelial", "cells,", "mesangial", "cells,", "interstitial", "cells,", "cardiomyocytes,", "fibroblasts,", "and", "neurons.", "<tag3>"], "wordsA": ["In", "PRX-102,", "the", "prh-alpha-GALA,", "naturally", "occurring", "as", "a", "homodimer,", "is", "PEGylated", "and", "cross-linked", "to", "support", "and", "reinforce", "the", "homodimeric", "structure,", "which", "is", "crucial", "for", "the", "enzymatic", "activity", "of", "this", "enzyme."], "wordsB": ["The", "absence", "or", "reduction", "of", "this", "enzymatic", "activity", "leads", "to", "the", "progressive", "accumulation", "of", "glycolipids,", "especially", "Gb3,", "in", "capillary", "endothelial", "cells,", "podocytes,", "tubular", "cells,", "glomerular", "endothelial", "cells,", "mesangial", "cells,", "interstitial", "cells,", "cardiomyocytes,", "fibroblasts,", "and", "neurons."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_18_item1_p96_s2", "idA": "1006281_17_item1_p64_s4", "sentA": "All patients that completed the trial have opted to continue to receive 1 mg/kg of PRX-102 in an open-label extension trial, 60-month extension study under which all patients have been switched to receive 1 mg/kg of the drug, the selected dose for our phase III studies of PRX-102.", "sentB": "Currently, the first 14 patients have completed the study, and four patients are currently in treatment and follow-up.", "type": 1, "words": ["<tag1>", "All", "patients", "that", "completed", "the", "trial", "have", "opted", "to", "continue", "to", "receive", "1", "mg/kg", "of", "PRX-102", "in", "an", "open-label", "extension", "trial,", "60-month", "extension", "study", "under", "which", "all", "patients", "have", "been", "switched", "to", "receive", "1", "mg/kg", "of", "the", "drug,", "the", "selected", "dose", "for", "our", "phase", "III", "studies", "of", "PRX-102.", "<tag2>", "Currently,", "the", "first", "14", "patients", "have", "completed", "the", "study,", "and", "four", "patients", "are", "currently", "in", "treatment", "and", "follow-up.", "<tag3>"], "wordsA": ["All", "patients", "that", "completed", "the", "trial", "have", "opted", "to", "continue", "to", "receive", "1", "mg/kg", "of", "PRX-102", "in", "an", "open-label", "extension", "trial,", "60-month", "extension", "study", "under", "which", "all", "patients", "have", "been", "switched", "to", "receive", "1", "mg/kg", "of", "the", "drug,", "the", "selected", "dose", "for", "our", "phase", "III", "studies", "of", "PRX-102."], "wordsB": ["Currently,", "the", "first", "14", "patients", "have", "completed", "the", "study,", "and", "four", "patients", "are", "currently", "in", "treatment", "and", "follow-up."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_18_item1_p6_s0", "idA": "1006281_17_item1_p81_s0", "sentA": "In January 2017, we announced positive interim results from the phase IIa clinical trial for the first 13 CF patients enrolled in the study.", "sentB": "In January 2018, FDA granted Fast Track designation to PRX-102.", "type": 1, "words": ["<tag1>", "In", "January", "2017,", "we", "announced", "positive", "interim", "results", "from", "the", "phase", "IIa", "clinical", "trial", "for", "the", "first", "13", "CF", "patients", "enrolled", "in", "the", "study.", "<tag2>", "In", "January", "2018,", "FDA", "granted", "Fast", "Track", "designation", "to", "PRX-102.", "<tag3>"], "wordsA": ["In", "January", "2017,", "we", "announced", "positive", "interim", "results", "from", "the", "phase", "IIa", "clinical", "trial", "for", "the", "first", "13", "CF", "patients", "enrolled", "in", "the", "study."], "wordsB": ["In", "January", "2018,", "FDA", "granted", "Fast", "Track", "designation", "to", "PRX-102."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_18_item1_p71_s1", "idA": "1006281_17_item1_p81_s0", "sentA": "In January 2017, we announced positive interim results from the phase IIa clinical trial for the first 13 CF patients enrolled in the study.", "sentB": "Patients who did not continue in the extension trial included female patients who became or planned to become pregnant, and therefore were unable to continue in accordance with the study protocol, and patients that relocated to a location where treatment was not available under the clinical study.", "type": 1, "words": ["<tag1>", "In", "January", "2017,", "we", "announced", "positive", "interim", "results", "from", "the", "phase", "IIa", "clinical", "trial", "for", "the", "first", "13", "CF", "patients", "enrolled", "in", "the", "study.", "<tag2>", "Patients", "who", "did", "not", "continue", "in", "the", "extension", "trial", "included", "female", "patients", "who", "became", "or", "planned", "to", "become", "pregnant,", "and", "therefore", "were", "unable", "to", "continue", "in", "accordance", "with", "the", "study", "protocol,", "and", "patients", "that", "relocated", "to", "a", "location", "where", "treatment", "was", "not", "available", "under", "the", "clinical", "study.", "<tag3>"], "wordsA": ["In", "January", "2017,", "we", "announced", "positive", "interim", "results", "from", "the", "phase", "IIa", "clinical", "trial", "for", "the", "first", "13", "CF", "patients", "enrolled", "in", "the", "study."], "wordsB": ["Patients", "who", "did", "not", "continue", "in", "the", "extension", "trial", "included", "female", "patients", "who", "became", "or", "planned", "to", "become", "pregnant,", "and", "therefore", "were", "unable", "to", "continue", "in", "accordance", "with", "the", "study", "protocol,", "and", "patients", "that", "relocated", "to", "a", "location", "where", "treatment", "was", "not", "available", "under", "the", "clinical", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_18_item1_p96_s7", "idA": "1006281_17_item1_p83_s0", "sentA": "Sputa available DNA samples were analyzed for approximately half of the patients in the phase II trial.", "sentB": "In addition, the majority of those patients show improvement in the study s additional efficacy endpoints, with 86% of the patients achieved an improvement in calprotectin, a protein biomarker present in the feces indicating intestinal inflammation, and 64% have an improved Geboes score, a histopathological scoring for the assessment of disease activity in ulcerative colitis.", "type": 1, "words": ["<tag1>", "Sputa", "available", "DNA", "samples", "were", "analyzed", "for", "approximately", "half", "of", "the", "patients", "in", "the", "phase", "II", "trial.", "<tag2>", "In", "addition,", "the", "majority", "of", "those", "patients", "show", "improvement", "in", "the", "study", "s", "additional", "efficacy", "endpoints,", "with", "86%", "of", "the", "patients", "achieved", "an", "improvement", "in", "calprotectin,", "a", "protein", "biomarker", "present", "in", "the", "feces", "indicating", "intestinal", "inflammation,", "and", "64%", "have", "an", "improved", "Geboes", "score,", "a", "histopathological", "scoring", "for", "the", "assessment", "of", "disease", "activity", "in", "ulcerative", "colitis.", "<tag3>"], "wordsA": ["Sputa", "available", "DNA", "samples", "were", "analyzed", "for", "approximately", "half", "of", "the", "patients", "in", "the", "phase", "II", "trial."], "wordsB": ["In", "addition,", "the", "majority", "of", "those", "patients", "show", "improvement", "in", "the", "study", "s", "additional", "efficacy", "endpoints,", "with", "86%", "of", "the", "patients", "achieved", "an", "improvement", "in", "calprotectin,", "a", "protein", "biomarker", "present", "in", "the", "feces", "indicating", "intestinal", "inflammation,", "and", "64%", "have", "an", "improved", "Geboes", "score,", "a", "histopathological", "scoring", "for", "the", "assessment", "of", "disease", "activity", "in", "ulcerative", "colitis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_12_item1_p134_s2", "idA": "1006281_11_item1_p100_s2", "sentA": "However, it has many side effects and the FDA has approved it only for administration to those patients who cannot be treated through enzyme replacement therapy, and, accordingly, have no other treatment alternative.", "sentB": "Furthermore, those patients who were followed specifically for their bone parameters using Quantitative Chemical Shift Imaging (QCSI) MRI continued to show bone marrow improvement over time.", "type": 1, "words": ["<tag1>", "However,", "it", "has", "many", "side", "effects", "and", "the", "FDA", "has", "approved", "it", "only", "for", "administration", "to", "those", "patients", "who", "cannot", "be", "treated", "through", "enzyme", "replacement", "therapy,", "and,", "accordingly,", "have", "no", "other", "treatment", "alternative.", "<tag2>", "Furthermore,", "those", "patients", "who", "were", "followed", "specifically", "for", "their", "bone", "parameters", "using", "Quantitative", "Chemical", "Shift", "Imaging", "(QCSI)", "MRI", "continued", "to", "show", "bone", "marrow", "improvement", "over", "time.", "<tag3>"], "wordsA": ["However,", "it", "has", "many", "side", "effects", "and", "the", "FDA", "has", "approved", "it", "only", "for", "administration", "to", "those", "patients", "who", "cannot", "be", "treated", "through", "enzyme", "replacement", "therapy,", "and,", "accordingly,", "have", "no", "other", "treatment", "alternative."], "wordsB": ["Furthermore,", "those", "patients", "who", "were", "followed", "specifically", "for", "their", "bone", "parameters", "using", "Quantitative", "Chemical", "Shift", "Imaging", "(QCSI)", "MRI", "continued", "to", "show", "bone", "marrow", "improvement", "over", "time."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_12_item1_p13_s2", "idA": "1006281_11_item1_p100_s2", "sentA": "However, it has many side effects and the FDA has approved it only for administration to those patients who cannot be treated through enzyme replacement therapy, and, accordingly, have no other treatment alternative.", "sentB": "Furthermore, those patients who were followed specifically for their bone parameters using Quantitative Chemical Shift Imaging (QCSI) MRI continued to show bone marrow improvement over time.", "type": 1, "words": ["<tag1>", "However,", "it", "has", "many", "side", "effects", "and", "the", "FDA", "has", "approved", "it", "only", "for", "administration", "to", "those", "patients", "who", "cannot", "be", "treated", "through", "enzyme", "replacement", "therapy,", "and,", "accordingly,", "have", "no", "other", "treatment", "alternative.", "<tag2>", "Furthermore,", "those", "patients", "who", "were", "followed", "specifically", "for", "their", "bone", "parameters", "using", "Quantitative", "Chemical", "Shift", "Imaging", "(QCSI)", "MRI", "continued", "to", "show", "bone", "marrow", "improvement", "over", "time.", "<tag3>"], "wordsA": ["However,", "it", "has", "many", "side", "effects", "and", "the", "FDA", "has", "approved", "it", "only", "for", "administration", "to", "those", "patients", "who", "cannot", "be", "treated", "through", "enzyme", "replacement", "therapy,", "and,", "accordingly,", "have", "no", "other", "treatment", "alternative."], "wordsB": ["Furthermore,", "those", "patients", "who", "were", "followed", "specifically", "for", "their", "bone", "parameters", "using", "Quantitative", "Chemical", "Shift", "Imaging", "(QCSI)", "MRI", "continued", "to", "show", "bone", "marrow", "improvement", "over", "time."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_12_item1_p85_s2", "idA": "1006281_11_item1_p100_s2", "sentA": "However, it has many side effects and the FDA has approved it only for administration to those patients who cannot be treated through enzyme replacement therapy, and, accordingly, have no other treatment alternative.", "sentB": "Furthermore, those patients who were followed specifically for their bone parameters using Quantitative Chemical Shift Imaging (QCSI) MRI continued to show bone marrow improvement over time.", "type": 1, "words": ["<tag1>", "However,", "it", "has", "many", "side", "effects", "and", "the", "FDA", "has", "approved", "it", "only", "for", "administration", "to", "those", "patients", "who", "cannot", "be", "treated", "through", "enzyme", "replacement", "therapy,", "and,", "accordingly,", "have", "no", "other", "treatment", "alternative.", "<tag2>", "Furthermore,", "those", "patients", "who", "were", "followed", "specifically", "for", "their", "bone", "parameters", "using", "Quantitative", "Chemical", "Shift", "Imaging", "(QCSI)", "MRI", "continued", "to", "show", "bone", "marrow", "improvement", "over", "time.", "<tag3>"], "wordsA": ["However,", "it", "has", "many", "side", "effects", "and", "the", "FDA", "has", "approved", "it", "only", "for", "administration", "to", "those", "patients", "who", "cannot", "be", "treated", "through", "enzyme", "replacement", "therapy,", "and,", "accordingly,", "have", "no", "other", "treatment", "alternative."], "wordsB": ["Furthermore,", "those", "patients", "who", "were", "followed", "specifically", "for", "their", "bone", "parameters", "using", "Quantitative", "Chemical", "Shift", "Imaging", "(QCSI)", "MRI", "continued", "to", "show", "bone", "marrow", "improvement", "over", "time."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_12_item1_p4_s4", "idA": "1006281_11_item1_p105_s1", "sentA": "Data produced from these preliminary development studies show that, relative to Cerezyme, taliglucerase alfa has:", "sentB": "At the time the NDA was submitted, full data from these trials was not available.", "type": 1, "words": ["<tag1>", "Data", "produced", "from", "these", "preliminary", "development", "studies", "show", "that,", "relative", "to", "Cerezyme,", "taliglucerase", "alfa", "has:", "<tag2>", "At", "the", "time", "the", "NDA", "was", "submitted,", "full", "data", "from", "these", "trials", "was", "not", "available.", "<tag3>"], "wordsA": ["Data", "produced", "from", "these", "preliminary", "development", "studies", "show", "that,", "relative", "to", "Cerezyme,", "taliglucerase", "alfa", "has:"], "wordsB": ["At", "the", "time", "the", "NDA", "was", "submitted,", "full", "data", "from", "these", "trials", "was", "not", "available."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_12_item1_p74_s2", "idA": "1006281_11_item1_p105_s1", "sentA": "Data produced from these preliminary development studies show that, relative to Cerezyme, taliglucerase alfa has:", "sentB": "At the time the NDA was submitted, full data from these trials was not available.", "type": 1, "words": ["<tag1>", "Data", "produced", "from", "these", "preliminary", "development", "studies", "show", "that,", "relative", "to", "Cerezyme,", "taliglucerase", "alfa", "has:", "<tag2>", "At", "the", "time", "the", "NDA", "was", "submitted,", "full", "data", "from", "these", "trials", "was", "not", "available.", "<tag3>"], "wordsA": ["Data", "produced", "from", "these", "preliminary", "development", "studies", "show", "that,", "relative", "to", "Cerezyme,", "taliglucerase", "alfa", "has:"], "wordsB": ["At", "the", "time", "the", "NDA", "was", "submitted,", "full", "data", "from", "these", "trials", "was", "not", "available."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_12_item1_p145_s2", "idA": "1006281_11_item1_p130_s1", "sentA": "In pre-clinical studies, PRX-102 demonstrated preliminary efficacy in a Fabry animal model.", "sentB": "Another patient experienced a hypersensitivity reaction, which was treated in a physician s office and resolved.", "type": 1, "words": ["<tag1>", "In", "pre-clinical", "studies,", "PRX-102", "demonstrated", "preliminary", "efficacy", "in", "a", "Fabry", "animal", "model.", "<tag2>", "Another", "patient", "experienced", "a", "hypersensitivity", "reaction,", "which", "was", "treated", "in", "a", "physician", "s", "office", "and", "resolved.", "<tag3>"], "wordsA": ["In", "pre-clinical", "studies,", "PRX-102", "demonstrated", "preliminary", "efficacy", "in", "a", "Fabry", "animal", "model."], "wordsB": ["Another", "patient", "experienced", "a", "hypersensitivity", "reaction,", "which", "was", "treated", "in", "a", "physician", "s", "office", "and", "resolved."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_12_item1_p165_s3", "idA": "1006281_11_item1_p143_s0", "sentA": "pr-antiTNF is a plant cell-expressed recombinant fusion protein made from the soluble form of the human TNF receptor (TNFR), fused to the Fc component of a human antibody domain.", "sentB": "The research highlights that a splice shift, either inherited or induced by environmental factors (e.g. neurotoxins), from the more common 'synaptic form' of acetylcholinesterase (AChE-S) to the monomeric 'read-through' variant of AChE (AChE-R), is important in conferring protection against Parkinson-like symptoms.", "type": 1, "words": ["<tag1>", "pr-antiTNF", "is", "a", "plant", "cell-expressed", "recombinant", "fusion", "protein", "made", "from", "the", "soluble", "form", "of", "the", "human", "TNF", "receptor", "(TNFR),", "fused", "to", "the", "Fc", "component", "of", "a", "human", "antibody", "domain.", "<tag2>", "The", "research", "highlights", "that", "a", "splice", "shift,", "either", "inherited", "or", "induced", "by", "environmental", "factors", "(e.g.", "neurotoxins),", "from", "the", "more", "common", "'synaptic", "form'", "of", "acetylcholinesterase", "(AChE-S)", "to", "the", "monomeric", "'read-through'", "variant", "of", "AChE", "(AChE-R),", "is", "important", "in", "conferring", "protection", "against", "Parkinson-like", "symptoms.", "<tag3>"], "wordsA": ["pr-antiTNF", "is", "a", "plant", "cell-expressed", "recombinant", "fusion", "protein", "made", "from", "the", "soluble", "form", "of", "the", "human", "TNF", "receptor", "(TNFR),", "fused", "to", "the", "Fc", "component", "of", "a", "human", "antibody", "domain."], "wordsB": ["The", "research", "highlights", "that", "a", "splice", "shift,", "either", "inherited", "or", "induced", "by", "environmental", "factors", "(e.g.", "neurotoxins),", "from", "the", "more", "common", "'synaptic", "form'", "of", "acetylcholinesterase", "(AChE-S)", "to", "the", "monomeric", "'read-through'", "variant", "of", "AChE", "(AChE-R),", "is", "important", "in", "conferring", "protection", "against", "Parkinson-like", "symptoms."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_12_item1_p40_s3", "idA": "1006281_11_item1_p14_s1", "sentA": "The treatment protocol was approved by the FDA in August 2009.", "sentB": "The IMS Institute for Healthcare Informatics reports that global biologic spending was $138 billion in 2010 ( Report by the IMS Institute for Healthcare Informatics , May 2011).", "type": 1, "words": ["<tag1>", "The", "treatment", "protocol", "was", "approved", "by", "the", "FDA", "in", "August", "2009.", "<tag2>", "The", "IMS", "Institute", "for", "Healthcare", "Informatics", "reports", "that", "global", "biologic", "spending", "was", "$138", "billion", "in", "2010", "(", "Report", "by", "the", "IMS", "Institute", "for", "Healthcare", "Informatics", ",", "May", "2011).", "<tag3>"], "wordsA": ["The", "treatment", "protocol", "was", "approved", "by", "the", "FDA", "in", "August", "2009."], "wordsB": ["The", "IMS", "Institute", "for", "Healthcare", "Informatics", "reports", "that", "global", "biologic", "spending", "was", "$138", "billion", "in", "2010", "(", "Report", "by", "the", "IMS", "Institute", "for", "Healthcare", "Informatics", ",", "May", "2011)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_12_item1_p235_s0", "idA": "1006281_11_item1_p176_s7", "sentA": "Total expected cost for such expansion is currently estimated to be approximately $25 million and the process is expected to be completed during 2012.", "sentB": "A new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.", "type": 1, "words": ["<tag1>", "Total", "expected", "cost", "for", "such", "expansion", "is", "currently", "estimated", "to", "be", "approximately", "$25", "million", "and", "the", "process", "is", "expected", "to", "be", "completed", "during", "2012.", "<tag2>", "A", "new", "Patient-Centered", "Outcomes", "Research", "Institute", "to", "oversee,", "identify", "priorities", "in,", "and", "conduct", "comparative", "clinical", "effectiveness", "research,", "along", "with", "funding", "for", "such", "research.", "<tag3>"], "wordsA": ["Total", "expected", "cost", "for", "such", "expansion", "is", "currently", "estimated", "to", "be", "approximately", "$25", "million", "and", "the", "process", "is", "expected", "to", "be", "completed", "during", "2012."], "wordsB": ["A", "new", "Patient-Centered", "Outcomes", "Research", "Institute", "to", "oversee,", "identify", "priorities", "in,", "and", "conduct", "comparative", "clinical", "effectiveness", "research,", "along", "with", "funding", "for", "such", "research."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_12_item1_p63_s5", "idA": "1006281_11_item1_p191_s0", "sentA": "The testing, manufacture, distribution, advertising and marketing of drug products are subject to extensive regulation by federal, state and local governmental authorities in the United States, including the FDA, and by similar authorities in other countries.", "sentB": "Pfizer has also taken an active, collaborative role in our ATU in France and similar programs in Brazil and other countries.", "type": 1, "words": ["<tag1>", "The", "testing,", "manufacture,", "distribution,", "advertising", "and", "marketing", "of", "drug", "products", "are", "subject", "to", "extensive", "regulation", "by", "federal,", "state", "and", "local", "governmental", "authorities", "in", "the", "United", "States,", "including", "the", "FDA,", "and", "by", "similar", "authorities", "in", "other", "countries.", "<tag2>", "Pfizer", "has", "also", "taken", "an", "active,", "collaborative", "role", "in", "our", "ATU", "in", "France", "and", "similar", "programs", "in", "Brazil", "and", "other", "countries.", "<tag3>"], "wordsA": ["The", "testing,", "manufacture,", "distribution,", "advertising", "and", "marketing", "of", "drug", "products", "are", "subject", "to", "extensive", "regulation", "by", "federal,", "state", "and", "local", "governmental", "authorities", "in", "the", "United", "States,", "including", "the", "FDA,", "and", "by", "similar", "authorities", "in", "other", "countries."], "wordsB": ["Pfizer", "has", "also", "taken", "an", "active,", "collaborative", "role", "in", "our", "ATU", "in", "France", "and", "similar", "programs", "in", "Brazil", "and", "other", "countries."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_12_item1_p145_s4", "idA": "1006281_11_item1_p196_s1", "sentA": "Phase II usually involves studies in a limited patient population to evaluate the effectiveness of the drug product in humans having the disease or medical condition for which the product is indicated, determine dosage tolerance and optimal dosage and identify possible common adverse effects and safety risks.", "sentB": "Additionally, all drug-related adverse effects were mild or moderate and transient in nature.", "type": 1, "words": ["<tag1>", "Phase", "II", "usually", "involves", "studies", "in", "a", "limited", "patient", "population", "to", "evaluate", "the", "effectiveness", "of", "the", "drug", "product", "in", "humans", "having", "the", "disease", "or", "medical", "condition", "for", "which", "the", "product", "is", "indicated,", "determine", "dosage", "tolerance", "and", "optimal", "dosage", "and", "identify", "possible", "common", "adverse", "effects", "and", "safety", "risks.", "<tag2>", "Additionally,", "all", "drug-related", "adverse", "effects", "were", "mild", "or", "moderate", "and", "transient", "in", "nature.", "<tag3>"], "wordsA": ["Phase", "II", "usually", "involves", "studies", "in", "a", "limited", "patient", "population", "to", "evaluate", "the", "effectiveness", "of", "the", "drug", "product", "in", "humans", "having", "the", "disease", "or", "medical", "condition", "for", "which", "the", "product", "is", "indicated,", "determine", "dosage", "tolerance", "and", "optimal", "dosage", "and", "identify", "possible", "common", "adverse", "effects", "and", "safety", "risks."], "wordsB": ["Additionally,", "all", "drug-related", "adverse", "effects", "were", "mild", "or", "moderate", "and", "transient", "in", "nature."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_12_item1_p242_s0", "idA": "1006281_11_item1_p216_s1", "sentA": "These benefits may include cash grants from the Israeli government and tax benefits, based upon, among other things, the location of the facility in which the investment is made and specific elections made by the grantee.", "sentB": "On July 14, 2009, the Israel Economic Efficiency Law (Legislation Amendments for Applying the Economic Plan for 2009 and 2010), 2009, became effective, stipulating, among other things, an additional gradual decrease in tax rates in 2011 and thereafter, as follows: 2011 24%, 2012 23%, 2013 22%, 2014 21%, 2015 20% and 2016 and thereafter 18%.", "type": 1, "words": ["<tag1>", "These", "benefits", "may", "include", "cash", "grants", "from", "the", "Israeli", "government", "and", "tax", "benefits,", "based", "upon,", "among", "other", "things,", "the", "location", "of", "the", "facility", "in", "which", "the", "investment", "is", "made", "and", "specific", "elections", "made", "by", "the", "grantee.", "<tag2>", "On", "July", "14,", "2009,", "the", "Israel", "Economic", "Efficiency", "Law", "(Legislation", "Amendments", "for", "Applying", "the", "Economic", "Plan", "for", "2009", "and", "2010),", "2009,", "became", "effective,", "stipulating,", "among", "other", "things,", "an", "additional", "gradual", "decrease", "in", "tax", "rates", "in", "2011", "and", "thereafter,", "as", "follows:", "2011", "24%,", "2012", "23%,", "2013", "22%,", "2014", "21%,", "2015", "20%", "and", "2016", "and", "thereafter", "18%.", "<tag3>"], "wordsA": ["These", "benefits", "may", "include", "cash", "grants", "from", "the", "Israeli", "government", "and", "tax", "benefits,", "based", "upon,", "among", "other", "things,", "the", "location", "of", "the", "facility", "in", "which", "the", "investment", "is", "made", "and", "specific", "elections", "made", "by", "the", "grantee."], "wordsB": ["On", "July", "14,", "2009,", "the", "Israel", "Economic", "Efficiency", "Law", "(Legislation", "Amendments", "for", "Applying", "the", "Economic", "Plan", "for", "2009", "and", "2010),", "2009,", "became", "effective,", "stipulating,", "among", "other", "things,", "an", "additional", "gradual", "decrease", "in", "tax", "rates", "in", "2011", "and", "thereafter,", "as", "follows:", "2011", "24%,", "2012", "23%,", "2013", "22%,", "2014", "21%,", "2015", "20%", "and", "2016", "and", "thereafter", "18%."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_12_item1_p5_s8", "idA": "1006281_11_item1_p239_s1", "sentA": "No assurance can be made that approval to any such transfer, if requested, will be granted.", "sentB": "A three-month extension cycle is the standard period granted.", "type": 1, "words": ["<tag1>", "No", "assurance", "can", "be", "made", "that", "approval", "to", "any", "such", "transfer,", "if", "requested,", "will", "be", "granted.", "<tag2>", "A", "three-month", "extension", "cycle", "is", "the", "standard", "period", "granted.", "<tag3>"], "wordsA": ["No", "assurance", "can", "be", "made", "that", "approval", "to", "any", "such", "transfer,", "if", "requested,", "will", "be", "granted."], "wordsB": ["A", "three-month", "extension", "cycle", "is", "the", "standard", "period", "granted."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_12_item1_p64_s9", "idA": "1006281_11_item1_p239_s1", "sentA": "No assurance can be made that approval to any such transfer, if requested, will be granted.", "sentB": "A three-month extension cycle is the standard period granted.", "type": 1, "words": ["<tag1>", "No", "assurance", "can", "be", "made", "that", "approval", "to", "any", "such", "transfer,", "if", "requested,", "will", "be", "granted.", "<tag2>", "A", "three-month", "extension", "cycle", "is", "the", "standard", "period", "granted.", "<tag3>"], "wordsA": ["No", "assurance", "can", "be", "made", "that", "approval", "to", "any", "such", "transfer,", "if", "requested,", "will", "be", "granted."], "wordsB": ["A", "three-month", "extension", "cycle", "is", "the", "standard", "period", "granted."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_12_item1_p75_s8", "idA": "1006281_11_item1_p239_s1", "sentA": "No assurance can be made that approval to any such transfer, if requested, will be granted.", "sentB": "A three-month extension cycle is the standard period granted.", "type": 1, "words": ["<tag1>", "No", "assurance", "can", "be", "made", "that", "approval", "to", "any", "such", "transfer,", "if", "requested,", "will", "be", "granted.", "<tag2>", "A", "three-month", "extension", "cycle", "is", "the", "standard", "period", "granted.", "<tag3>"], "wordsA": ["No", "assurance", "can", "be", "made", "that", "approval", "to", "any", "such", "transfer,", "if", "requested,", "will", "be", "granted."], "wordsB": ["A", "three-month", "extension", "cycle", "is", "the", "standard", "period", "granted."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_12_item1_p143_s3", "idA": "1006281_11_item1_p244_s0", "sentA": "Another provision in the amendment concerns the transfer of manufacturing rights.", "sentB": "Adverse events in the extension trial included headache, pruritus, abdominal pain, infusion related reactions (dizziness, chills, nausea), muscle spasm and fixed drug eruption.", "type": 1, "words": ["<tag1>", "Another", "provision", "in", "the", "amendment", "concerns", "the", "transfer", "of", "manufacturing", "rights.", "<tag2>", "Adverse", "events", "in", "the", "extension", "trial", "included", "headache,", "pruritus,", "abdominal", "pain,", "infusion", "related", "reactions", "(dizziness,", "chills,", "nausea),", "muscle", "spasm", "and", "fixed", "drug", "eruption.", "<tag3>"], "wordsA": ["Another", "provision", "in", "the", "amendment", "concerns", "the", "transfer", "of", "manufacturing", "rights."], "wordsB": ["Adverse", "events", "in", "the", "extension", "trial", "included", "headache,", "pruritus,", "abdominal", "pain,", "infusion", "related", "reactions", "(dizziness,", "chills,", "nausea),", "muscle", "spasm", "and", "fixed", "drug", "eruption."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_12_item1_p145_s3", "idA": "1006281_11_item1_p261_s2", "sentA": "We intend to continue to hire additional employees in research and development, manufacturing and administration in order to meet our operating plans.", "sentB": "The patient declined to continue infusions with premedication.", "type": 1, "words": ["<tag1>", "We", "intend", "to", "continue", "to", "hire", "additional", "employees", "in", "research", "and", "development,", "manufacturing", "and", "administration", "in", "order", "to", "meet", "our", "operating", "plans.", "<tag2>", "The", "patient", "declined", "to", "continue", "infusions", "with", "premedication.", "<tag3>"], "wordsA": ["We", "intend", "to", "continue", "to", "hire", "additional", "employees", "in", "research", "and", "development,", "manufacturing", "and", "administration", "in", "order", "to", "meet", "our", "operating", "plans."], "wordsB": ["The", "patient", "declined", "to", "continue", "infusions", "with", "premedication."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_12_item1_p215_s2", "idA": "1006281_11_item1_p52_s4", "sentA": "This system also reduces ongoing production and monitoring costs typically incurred by companies using mammalian cell-based expression technologies.", "sentB": "Competitors developing alternative expression technologies include Crucell N.V. (which was acquired by Johnson Johnson during 2010), Shire and GlycoFi, Inc. (which was acquired by Merck Co. Inc.).", "type": 1, "words": ["<tag1>", "This", "system", "also", "reduces", "ongoing", "production", "and", "monitoring", "costs", "typically", "incurred", "by", "companies", "using", "mammalian", "cell-based", "expression", "technologies.", "<tag2>", "Competitors", "developing", "alternative", "expression", "technologies", "include", "Crucell", "N.V.", "(which", "was", "acquired", "by", "Johnson", "Johnson", "during", "2010),", "Shire", "and", "GlycoFi,", "Inc.", "(which", "was", "acquired", "by", "Merck", "Co.", "Inc.).", "<tag3>"], "wordsA": ["This", "system", "also", "reduces", "ongoing", "production", "and", "monitoring", "costs", "typically", "incurred", "by", "companies", "using", "mammalian", "cell-based", "expression", "technologies."], "wordsB": ["Competitors", "developing", "alternative", "expression", "technologies", "include", "Crucell", "N.V.", "(which", "was", "acquired", "by", "Johnson", "Johnson", "during", "2010),", "Shire", "and", "GlycoFi,", "Inc.", "(which", "was", "acquired", "by", "Merck", "Co.", "Inc.)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_12_item1_p142_s2", "idA": "1006281_11_item1_p75_s10", "sentA": "Hypersensitivity reactions were not reported in this patient group.", "sentB": "Treatment of this patient has been continued with premedication for an additional 32 months without any treatment related adverse event reported.", "type": 1, "words": ["<tag1>", "Hypersensitivity", "reactions", "were", "not", "reported", "in", "this", "patient", "group.", "<tag2>", "Treatment", "of", "this", "patient", "has", "been", "continued", "with", "premedication", "for", "an", "additional", "32", "months", "without", "any", "treatment", "related", "adverse", "event", "reported.", "<tag3>"], "wordsA": ["Hypersensitivity", "reactions", "were", "not", "reported", "in", "this", "patient", "group."], "wordsB": ["Treatment", "of", "this", "patient", "has", "been", "continued", "with", "premedication", "for", "an", "additional", "32", "months", "without", "any", "treatment", "related", "adverse", "event", "reported."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_12_item1_p92_s0", "idA": "1006281_11_item1_p86_s0", "sentA": "We believe that oral delivery of taliglucerase alfa presents a number of advantages.", "sentB": "Increased Glycan Efficacy and Consistency .", "type": 1, "words": ["<tag1>", "We", "believe", "that", "oral", "delivery", "of", "taliglucerase", "alfa", "presents", "a", "number", "of", "advantages.", "<tag2>", "Increased", "Glycan", "Efficacy", "and", "Consistency", ".", "<tag3>"], "wordsA": ["We", "believe", "that", "oral", "delivery", "of", "taliglucerase", "alfa", "presents", "a", "number", "of", "advantages."], "wordsB": ["Increased", "Glycan", "Efficacy", "and", "Consistency", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_15_item1_p89_s1", "idA": "1006281_14_item1_p106_s0", "sentA": "PRX-102 has demonstrated a significantly longer circular half-life than that of Replagal, over 40 times greater.", "sentB": "Females (n=2) demonstrated a -2.4 ng/mL mean change in Lyso-Gb3 and a -0.4 g/mL mean change in plasma Gb3.", "type": 1, "words": ["<tag1>", "PRX-102", "has", "demonstrated", "a", "significantly", "longer", "circular", "half-life", "than", "that", "of", "Replagal,", "over", "40", "times", "greater.", "<tag2>", "Females", "(n=2)", "demonstrated", "a", "-2.4", "ng/mL", "mean", "change", "in", "Lyso-Gb3", "and", "a", "-0.4", "g/mL", "mean", "change", "in", "plasma", "Gb3.", "<tag3>"], "wordsA": ["PRX-102", "has", "demonstrated", "a", "significantly", "longer", "circular", "half-life", "than", "that", "of", "Replagal,", "over", "40", "times", "greater."], "wordsB": ["Females", "(n=2)", "demonstrated", "a", "-2.4", "ng/mL", "mean", "change", "in", "Lyso-Gb3", "and", "a", "-0.4", "g/mL", "mean", "change", "in", "plasma", "Gb3."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_15_item1_p89_s2", "idA": "1006281_14_item1_p106_s0", "sentA": "PRX-102 has demonstrated a significantly longer circular half-life than that of Replagal, over 40 times greater.", "sentB": "Males (n=4) demonstrated a -96.2 ng/mL and a -1.3 g/mL change, respectively.", "type": 1, "words": ["<tag1>", "PRX-102", "has", "demonstrated", "a", "significantly", "longer", "circular", "half-life", "than", "that", "of", "Replagal,", "over", "40", "times", "greater.", "<tag2>", "Males", "(n=4)", "demonstrated", "a", "-96.2", "ng/mL", "and", "a", "-1.3", "g/mL", "change,", "respectively.", "<tag3>"], "wordsA": ["PRX-102", "has", "demonstrated", "a", "significantly", "longer", "circular", "half-life", "than", "that", "of", "Replagal,", "over", "40", "times", "greater."], "wordsB": ["Males", "(n=4)", "demonstrated", "a", "-96.2", "ng/mL", "and", "a", "-1.3", "g/mL", "change,", "respectively."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_15_item1_p109_s0", "idA": "1006281_14_item1_p108_s2", "sentA": "The trial is designed to enroll 18 adult Fabry patients, each in one of three dosing groups.", "sentB": "AIR DNase has an actin inhibition resistance that is designed to improve lung function and lower the incidence of recurrent infections by enhancing the enzyme s efficacy in patients sputa.", "type": 1, "words": ["<tag1>", "The", "trial", "is", "designed", "to", "enroll", "18", "adult", "Fabry", "patients,", "each", "in", "one", "of", "three", "dosing", "groups.", "<tag2>", "AIR", "DNase", "has", "an", "actin", "inhibition", "resistance", "that", "is", "designed", "to", "improve", "lung", "function", "and", "lower", "the", "incidence", "of", "recurrent", "infections", "by", "enhancing", "the", "enzyme", "s", "efficacy", "in", "patients", "sputa.", "<tag3>"], "wordsA": ["The", "trial", "is", "designed", "to", "enroll", "18", "adult", "Fabry", "patients,", "each", "in", "one", "of", "three", "dosing", "groups."], "wordsB": ["AIR", "DNase", "has", "an", "actin", "inhibition", "resistance", "that", "is", "designed", "to", "improve", "lung", "function", "and", "lower", "the", "incidence", "of", "recurrent", "infections", "by", "enhancing", "the", "enzyme", "s", "efficacy", "in", "patients", "sputa."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_15_item1_p22_s1", "idA": "1006281_14_item1_p108_s2", "sentA": "The trial is designed to enroll 18 adult Fabry patients, each in one of three dosing groups.", "sentB": "AIR DNase has an actin inhibition resistance that is designed to improve lung function and lower the incidence of recurrent infections by enhancing the enzyme s efficacy in patients sputa.", "type": 1, "words": ["<tag1>", "The", "trial", "is", "designed", "to", "enroll", "18", "adult", "Fabry", "patients,", "each", "in", "one", "of", "three", "dosing", "groups.", "<tag2>", "AIR", "DNase", "has", "an", "actin", "inhibition", "resistance", "that", "is", "designed", "to", "improve", "lung", "function", "and", "lower", "the", "incidence", "of", "recurrent", "infections", "by", "enhancing", "the", "enzyme", "s", "efficacy", "in", "patients", "sputa.", "<tag3>"], "wordsA": ["The", "trial", "is", "designed", "to", "enroll", "18", "adult", "Fabry", "patients,", "each", "in", "one", "of", "three", "dosing", "groups."], "wordsB": ["AIR", "DNase", "has", "an", "actin", "inhibition", "resistance", "that", "is", "designed", "to", "improve", "lung", "function", "and", "lower", "the", "incidence", "of", "recurrent", "infections", "by", "enhancing", "the", "enzyme", "s", "efficacy", "in", "patients", "sputa."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_15_item1_p21_s1", "idA": "1006281_14_item1_p116_s0", "sentA": "Our oral taliglucerase alfa product candidate is a recombinant form of the GCD enzyme, not a small molecule.", "sentB": "Oral anti-TNF represents a novel mode of administering a recombinant anti-TNF protein.", "type": 1, "words": ["<tag1>", "Our", "oral", "taliglucerase", "alfa", "product", "candidate", "is", "a", "recombinant", "form", "of", "the", "GCD", "enzyme,", "not", "a", "small", "molecule.", "<tag2>", "Oral", "anti-TNF", "represents", "a", "novel", "mode", "of", "administering", "a", "recombinant", "anti-TNF", "protein.", "<tag3>"], "wordsA": ["Our", "oral", "taliglucerase", "alfa", "product", "candidate", "is", "a", "recombinant", "form", "of", "the", "GCD", "enzyme,", "not", "a", "small", "molecule."], "wordsB": ["Oral", "anti-TNF", "represents", "a", "novel", "mode", "of", "administering", "a", "recombinant", "anti-TNF", "protein."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_15_item1_p99_s0", "idA": "1006281_14_item1_p122_s1", "sentA": "C max analysis showed an average increase of over 100% in enzymatic activity from base line, with an increase ranging from approximately 50% to 350% among the different, individual patients in the study.", "sentB": "AntiTNF drugs represent the biggest category of biological drugs in the world today with combined sales of over $20 billion a year.", "type": 1, "words": ["<tag1>", "C", "max", "analysis", "showed", "an", "average", "increase", "of", "over", "100%", "in", "enzymatic", "activity", "from", "base", "line,", "with", "an", "increase", "ranging", "from", "approximately", "50%", "to", "350%", "among", "the", "different,", "individual", "patients", "in", "the", "study.", "<tag2>", "AntiTNF", "drugs", "represent", "the", "biggest", "category", "of", "biological", "drugs", "in", "the", "world", "today", "with", "combined", "sales", "of", "over", "$20", "billion", "a", "year.", "<tag3>"], "wordsA": ["C", "max", "analysis", "showed", "an", "average", "increase", "of", "over", "100%", "in", "enzymatic", "activity", "from", "base", "line,", "with", "an", "increase", "ranging", "from", "approximately", "50%", "to", "350%", "among", "the", "different,", "individual", "patients", "in", "the", "study."], "wordsB": ["AntiTNF", "drugs", "represent", "the", "biggest", "category", "of", "biological", "drugs", "in", "the", "world", "today", "with", "combined", "sales", "of", "over", "$20", "billion", "a", "year."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_15_item1_p113_s0", "idA": "1006281_14_item1_p123_s3", "sentA": "Thus, with a daily oral administration of oral GCD, we expect to achieve a steady state level of active GCD enzyme in the blood circulation of patients similar to the physiological state in healthy individuals.", "sentB": "Subjects receive once daily oral administrations of PRX-112 for five consecutive days at each dose, with a two-day washout period between doses.", "type": 1, "words": ["<tag1>", "Thus,", "with", "a", "daily", "oral", "administration", "of", "oral", "GCD,", "we", "expect", "to", "achieve", "a", "steady", "state", "level", "of", "active", "GCD", "enzyme", "in", "the", "blood", "circulation", "of", "patients", "similar", "to", "the", "physiological", "state", "in", "healthy", "individuals.", "<tag2>", "Subjects", "receive", "once", "daily", "oral", "administrations", "of", "PRX-112", "for", "five", "consecutive", "days", "at", "each", "dose,", "with", "a", "two-day", "washout", "period", "between", "doses.", "<tag3>"], "wordsA": ["Thus,", "with", "a", "daily", "oral", "administration", "of", "oral", "GCD,", "we", "expect", "to", "achieve", "a", "steady", "state", "level", "of", "active", "GCD", "enzyme", "in", "the", "blood", "circulation", "of", "patients", "similar", "to", "the", "physiological", "state", "in", "healthy", "individuals."], "wordsB": ["Subjects", "receive", "once", "daily", "oral", "administrations", "of", "PRX-112", "for", "five", "consecutive", "days", "at", "each", "dose,", "with", "a", "two-day", "washout", "period", "between", "doses."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_15_item1_p22_s0", "idA": "1006281_14_item1_p133_s1", "sentA": "DNase I cleaves extracellular DNA and thins the thick mucus that accumulates in the lungs of Cystic Fibrosis patients.", "sentB": "AIR DNase (PRX-110) for Cystic Fibrosis .", "type": 1, "words": ["<tag1>", "DNase", "I", "cleaves", "extracellular", "DNA", "and", "thins", "the", "thick", "mucus", "that", "accumulates", "in", "the", "lungs", "of", "Cystic", "Fibrosis", "patients.", "<tag2>", "AIR", "DNase", "(PRX-110)", "for", "Cystic", "Fibrosis", ".", "<tag3>"], "wordsA": ["DNase", "I", "cleaves", "extracellular", "DNA", "and", "thins", "the", "thick", "mucus", "that", "accumulates", "in", "the", "lungs", "of", "Cystic", "Fibrosis", "patients."], "wordsB": ["AIR", "DNase", "(PRX-110)", "for", "Cystic", "Fibrosis", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_15_item1_p24_s0", "idA": "1006281_14_item1_p141_s2", "sentA": "The initial term of the technology transfer is seven years.", "sentB": "The initial clinical data generated for this compound in pre-clinical and clinical trials is promising.", "type": 1, "words": ["<tag1>", "The", "initial", "term", "of", "the", "technology", "transfer", "is", "seven", "years.", "<tag2>", "The", "initial", "clinical", "data", "generated", "for", "this", "compound", "in", "pre-clinical", "and", "clinical", "trials", "is", "promising.", "<tag3>"], "wordsA": ["The", "initial", "term", "of", "the", "technology", "transfer", "is", "seven", "years."], "wordsB": ["The", "initial", "clinical", "data", "generated", "for", "this", "compound", "in", "pre-clinical", "and", "clinical", "trials", "is", "promising."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_15_item1_p19_s2", "idA": "1006281_14_item1_p29_s2", "sentA": "In addition, proteins produced by our ProCellEx system maintain the biological activity that characterize that of the naturally-produced proteins.", "sentB": "The strategy was the culmination of two month of intensive review by our management of the company s internal resources and of the markets in which we think we can operate.", "type": 1, "words": ["<tag1>", "In", "addition,", "proteins", "produced", "by", "our", "ProCellEx", "system", "maintain", "the", "biological", "activity", "that", "characterize", "that", "of", "the", "naturally-produced", "proteins.", "<tag2>", "The", "strategy", "was", "the", "culmination", "of", "two", "month", "of", "intensive", "review", "by", "our", "management", "of", "the", "company", "s", "internal", "resources", "and", "of", "the", "markets", "in", "which", "we", "think", "we", "can", "operate.", "<tag3>"], "wordsA": ["In", "addition,", "proteins", "produced", "by", "our", "ProCellEx", "system", "maintain", "the", "biological", "activity", "that", "characterize", "that", "of", "the", "naturally-produced", "proteins."], "wordsB": ["The", "strategy", "was", "the", "culmination", "of", "two", "month", "of", "intensive", "review", "by", "our", "management", "of", "the", "company", "s", "internal", "resources", "and", "of", "the", "markets", "in", "which", "we", "think", "we", "can", "operate."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_15_item1_p53_s0", "idA": "1006281_14_item1_p58_s0", "sentA": "Leverage Our ProCellEx System to Potentially Enable the Oral Administration of Active Therapeutic Enzymes.", "sentB": "Our ProCellEx system entails a lower cost of scale-up and of production.", "type": 1, "words": ["<tag1>", "Leverage", "Our", "ProCellEx", "System", "to", "Potentially", "Enable", "the", "Oral", "Administration", "of", "Active", "Therapeutic", "Enzymes.", "<tag2>", "Our", "ProCellEx", "system", "entails", "a", "lower", "cost", "of", "scale-up", "and", "of", "production.", "<tag3>"], "wordsA": ["Leverage", "Our", "ProCellEx", "System", "to", "Potentially", "Enable", "the", "Oral", "Administration", "of", "Active", "Therapeutic", "Enzymes."], "wordsB": ["Our", "ProCellEx", "system", "entails", "a", "lower", "cost", "of", "scale-up", "and", "of", "production."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_15_item1_p21_s0", "idA": "1006281_14_item1_p81_s2", "sentA": "We also initiated a home care treatment program for patients enrolled in the extension study.", "sentB": "Oral Anti-TNF (PRX-106) Anti Inflammatory .", "type": 1, "words": ["<tag1>", "We", "also", "initiated", "a", "home", "care", "treatment", "program", "for", "patients", "enrolled", "in", "the", "extension", "study.", "<tag2>", "Oral", "Anti-TNF", "(PRX-106)", "Anti", "Inflammatory", ".", "<tag3>"], "wordsA": ["We", "also", "initiated", "a", "home", "care", "treatment", "program", "for", "patients", "enrolled", "in", "the", "extension", "study."], "wordsB": ["Oral", "Anti-TNF", "(PRX-106)", "Anti", "Inflammatory", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_15_item1_p19_s0", "idA": "1006281_14_item1_p85_s0", "sentA": "In February 2013, we announced interim data from 23 adult patients enrolled in our extension trial.", "sentB": "In January 2015, we announced our newly implemented strategy for accelerated growth.", "type": 1, "words": ["<tag1>", "In", "February", "2013,", "we", "announced", "interim", "data", "from", "23", "adult", "patients", "enrolled", "in", "our", "extension", "trial.", "<tag2>", "In", "January", "2015,", "we", "announced", "our", "newly", "implemented", "strategy", "for", "accelerated", "growth.", "<tag3>"], "wordsA": ["In", "February", "2013,", "we", "announced", "interim", "data", "from", "23", "adult", "patients", "enrolled", "in", "our", "extension", "trial."], "wordsB": ["In", "January", "2015,", "we", "announced", "our", "newly", "implemented", "strategy", "for", "accelerated", "growth."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_15_item1_p87_s1", "idA": "1006281_14_item1_p88_s1", "sentA": "In the extension trial, at 36 months, both groups demonstrated clinically significant mean reductions in liver volume; reductions of 19.0% in the 60 U/kg group and of 21.0% in the 30 U/kg group; patients with Hepatomegaly demonstrated a reduction in liver volume of 30.0% in the 60 U/kg group and of 22.0% in the 30 U/kg group.", "sentB": "Using the BLISS method, a reduction in the rate of 82.2% for males, 65.4% for females and 75.5% for males and females combined were observed.", "type": 1, "words": ["<tag1>", "In", "the", "extension", "trial,", "at", "36", "months,", "both", "groups", "demonstrated", "clinically", "significant", "mean", "reductions", "in", "liver", "volume;", "reductions", "of", "19.0%", "in", "the", "60", "U/kg", "group", "and", "of", "21.0%", "in", "the", "30", "U/kg", "group;", "patients", "with", "Hepatomegaly", "demonstrated", "a", "reduction", "in", "liver", "volume", "of", "30.0%", "in", "the", "60", "U/kg", "group", "and", "of", "22.0%", "in", "the", "30", "U/kg", "group.", "<tag2>", "Using", "the", "BLISS", "method,", "a", "reduction", "in", "the", "rate", "of", "82.2%", "for", "males,", "65.4%", "for", "females", "and", "75.5%", "for", "males", "and", "females", "combined", "were", "observed.", "<tag3>"], "wordsA": ["In", "the", "extension", "trial,", "at", "36", "months,", "both", "groups", "demonstrated", "clinically", "significant", "mean", "reductions", "in", "liver", "volume;", "reductions", "of", "19.0%", "in", "the", "60", "U/kg", "group", "and", "of", "21.0%", "in", "the", "30", "U/kg", "group;", "patients", "with", "Hepatomegaly", "demonstrated", "a", "reduction", "in", "liver", "volume", "of", "30.0%", "in", "the", "60", "U/kg", "group", "and", "of", "22.0%", "in", "the", "30", "U/kg", "group."], "wordsB": ["Using", "the", "BLISS", "method,", "a", "reduction", "in", "the", "rate", "of", "82.2%", "for", "males,", "65.4%", "for", "females", "and", "75.5%", "for", "males", "and", "females", "combined", "were", "observed."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_15_item1_p95_s1", "idA": "1006281_14_item1_p8_s3", "sentA": "The initial term of the technology transfer is seven years.", "sentB": "Of these eight patients, only two patients, or 33% of the 0.2 mg/kg dose cohort, developed antibodies.", "type": 1, "words": ["<tag1>", "The", "initial", "term", "of", "the", "technology", "transfer", "is", "seven", "years.", "<tag2>", "Of", "these", "eight", "patients,", "only", "two", "patients,", "or", "33%", "of", "the", "0.2", "mg/kg", "dose", "cohort,", "developed", "antibodies.", "<tag3>"], "wordsA": ["The", "initial", "term", "of", "the", "technology", "transfer", "is", "seven", "years."], "wordsB": ["Of", "these", "eight", "patients,", "only", "two", "patients,", "or", "33%", "of", "the", "0.2", "mg/kg", "dose", "cohort,", "developed", "antibodies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_15_item1_p87_s3", "idA": "1006281_14_item1_p90_s2", "sentA": "In the extension trial, at 36 months, mean reductions in chitotriosidase activity were demonstrated by both groups; a reduction of 83.0% in the 60 U/kg group and of 73.5% in the 30 U/kg group.", "sentB": "Applying the semi quantitative scoring method, commonly used by approved enzyme replacement therapies, PRX-102 demonstrated a reduction of 69.6% in abnormal capillary score.", "type": 1, "words": ["<tag1>", "In", "the", "extension", "trial,", "at", "36", "months,", "mean", "reductions", "in", "chitotriosidase", "activity", "were", "demonstrated", "by", "both", "groups;", "a", "reduction", "of", "83.0%", "in", "the", "60", "U/kg", "group", "and", "of", "73.5%", "in", "the", "30", "U/kg", "group.", "<tag2>", "Applying", "the", "semi", "quantitative", "scoring", "method,", "commonly", "used", "by", "approved", "enzyme", "replacement", "therapies,", "PRX-102", "demonstrated", "a", "reduction", "of", "69.6%", "in", "abnormal", "capillary", "score.", "<tag3>"], "wordsA": ["In", "the", "extension", "trial,", "at", "36", "months,", "mean", "reductions", "in", "chitotriosidase", "activity", "were", "demonstrated", "by", "both", "groups;", "a", "reduction", "of", "83.0%", "in", "the", "60", "U/kg", "group", "and", "of", "73.5%", "in", "the", "30", "U/kg", "group."], "wordsB": ["Applying", "the", "semi", "quantitative", "scoring", "method,", "commonly", "used", "by", "approved", "enzyme", "replacement", "therapies,", "PRX-102", "demonstrated", "a", "reduction", "of", "69.6%", "in", "abnormal", "capillary", "score."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_15_item1_p88_s0", "idA": "1006281_14_item1_p95_s6", "sentA": "Lastly, the chitotriosidase activity decreased from baseline, with a 66.0% reduction in patients receiving 60 U/kg and a 58.0% reduction in patients receiving 30 U/kg.", "sentB": "Using the well-accepted Brief Pain Inventory scale, a 100% reduction in pain at its worst, a 60.0% reduction in mean severity, and 78.8% reduction on mean interference (which includes walking, working, sleeping, enjoyment of life and others) were observed.", "type": 1, "words": ["<tag1>", "Lastly,", "the", "chitotriosidase", "activity", "decreased", "from", "baseline,", "with", "a", "66.0%", "reduction", "in", "patients", "receiving", "60", "U/kg", "and", "a", "58.0%", "reduction", "in", "patients", "receiving", "30", "U/kg.", "<tag2>", "Using", "the", "well-accepted", "Brief", "Pain", "Inventory", "scale,", "a", "100%", "reduction", "in", "pain", "at", "its", "worst,", "a", "60.0%", "reduction", "in", "mean", "severity,", "and", "78.8%", "reduction", "on", "mean", "interference", "(which", "includes", "walking,", "working,", "sleeping,", "enjoyment", "of", "life", "and", "others)", "were", "observed.", "<tag3>"], "wordsA": ["Lastly,", "the", "chitotriosidase", "activity", "decreased", "from", "baseline,", "with", "a", "66.0%", "reduction", "in", "patients", "receiving", "60", "U/kg", "and", "a", "58.0%", "reduction", "in", "patients", "receiving", "30", "U/kg."], "wordsB": ["Using", "the", "well-accepted", "Brief", "Pain", "Inventory", "scale,", "a", "100%", "reduction", "in", "pain", "at", "its", "worst,", "a", "60.0%", "reduction", "in", "mean", "severity,", "and", "78.8%", "reduction", "on", "mean", "interference", "(which", "includes", "walking,", "working,", "sleeping,", "enjoyment", "of", "life", "and", "others)", "were", "observed."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_15_item1_p94_s2", "idA": "1006281_14_item1_p97_s3", "sentA": "Five taliglucerase alfa treated patients had a Ff below the threshold that relates to complication risk ( 0.23) at baseline (median (n=8) 0.19, range 0.11 0.35).", "sentB": "For this patient, anti PRX-102 IgG was negative and anti PRX-102 IgE was positive at baseline.", "type": 1, "words": ["<tag1>", "Five", "taliglucerase", "alfa", "treated", "patients", "had", "a", "Ff", "below", "the", "threshold", "that", "relates", "to", "complication", "risk", "(", "0.23)", "at", "baseline", "(median", "(n=8)", "0.19,", "range", "0.11", "0.35).", "<tag2>", "For", "this", "patient,", "anti", "PRX-102", "IgG", "was", "negative", "and", "anti", "PRX-102", "IgE", "was", "positive", "at", "baseline.", "<tag3>"], "wordsA": ["Five", "taliglucerase", "alfa", "treated", "patients", "had", "a", "Ff", "below", "the", "threshold", "that", "relates", "to", "complication", "risk", "(", "0.23)", "at", "baseline", "(median", "(n=8)", "0.19,", "range", "0.11", "0.35)."], "wordsB": ["For", "this", "patient,", "anti", "PRX-102", "IgG", "was", "negative", "and", "anti", "PRX-102", "IgE", "was", "positive", "at", "baseline."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_16_item1_p87_s0", "idA": "1006281_15_item1_p106_s0", "sentA": "PRX-110, or AIR DNase, is our plant cell recombinant form of human deoxyribonuclease I (DNase I) that we are developing for the treatment of Cystic Fibrosis, to be administered by inhalation.", "sentB": "Actin, a potent inhibitor of DNase, is found in high concentration in CF patients sputum.", "type": 1, "words": ["<tag1>", "PRX-110,", "or", "AIR", "DNase,", "is", "our", "plant", "cell", "recombinant", "form", "of", "human", "deoxyribonuclease", "I", "(DNase", "I)", "that", "we", "are", "developing", "for", "the", "treatment", "of", "Cystic", "Fibrosis,", "to", "be", "administered", "by", "inhalation.", "<tag2>", "Actin,", "a", "potent", "inhibitor", "of", "DNase,", "is", "found", "in", "high", "concentration", "in", "CF", "patients", "sputum.", "<tag3>"], "wordsA": ["PRX-110,", "or", "AIR", "DNase,", "is", "our", "plant", "cell", "recombinant", "form", "of", "human", "deoxyribonuclease", "I", "(DNase", "I)", "that", "we", "are", "developing", "for", "the", "treatment", "of", "Cystic", "Fibrosis,", "to", "be", "administered", "by", "inhalation."], "wordsB": ["Actin,", "a", "potent", "inhibitor", "of", "DNase,", "is", "found", "in", "high", "concentration", "in", "CF", "patients", "sputum."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_16_item1_p87_s1", "idA": "1006281_15_item1_p110_s0", "sentA": "We plan to initiate clinical efficacy trials of AIR DNase for the treatment of Cystic Fibrosis during 2015.", "sentB": "As demonstrated in Figure 1, the activity of AIR DNase remains almost with no change in the relevant actin concentration found in CF patients while Pulmozyme is degraded significantly.", "type": 1, "words": ["<tag1>", "We", "plan", "to", "initiate", "clinical", "efficacy", "trials", "of", "AIR", "DNase", "for", "the", "treatment", "of", "Cystic", "Fibrosis", "during", "2015.", "<tag2>", "As", "demonstrated", "in", "Figure", "1,", "the", "activity", "of", "AIR", "DNase", "remains", "almost", "with", "no", "change", "in", "the", "relevant", "actin", "concentration", "found", "in", "CF", "patients", "while", "Pulmozyme", "is", "degraded", "significantly.", "<tag3>"], "wordsA": ["We", "plan", "to", "initiate", "clinical", "efficacy", "trials", "of", "AIR", "DNase", "for", "the", "treatment", "of", "Cystic", "Fibrosis", "during", "2015."], "wordsB": ["As", "demonstrated", "in", "Figure", "1,", "the", "activity", "of", "AIR", "DNase", "remains", "almost", "with", "no", "change", "in", "the", "relevant", "actin", "concentration", "found", "in", "CF", "patients", "while", "Pulmozyme", "is", "degraded", "significantly."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_16_item1_p97_s4", "idA": "1006281_15_item1_p114_s0", "sentA": "An initial analysis of the results demonstrates that oral GCD was well tolerated.", "sentB": "Evaluations included pharmacokinetics, serum cytokines and an FACS analysis of T-cell population.", "type": 1, "words": ["<tag1>", "An", "initial", "analysis", "of", "the", "results", "demonstrates", "that", "oral", "GCD", "was", "well", "tolerated.", "<tag2>", "Evaluations", "included", "pharmacokinetics,", "serum", "cytokines", "and", "an", "FACS", "analysis", "of", "T-cell", "population.", "<tag3>"], "wordsA": ["An", "initial", "analysis", "of", "the", "results", "demonstrates", "that", "oral", "GCD", "was", "well", "tolerated."], "wordsB": ["Evaluations", "included", "pharmacokinetics,", "serum", "cytokines", "and", "an", "FACS", "analysis", "of", "T-cell", "population."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_16_item1_p136_s0", "idA": "1006281_15_item1_p144_s0", "sentA": "With respect to taliglucerase alfa, we have licensed the rights to two patents from Virginia Tech Intellectual Properties, Inc., or Virginia Tech, that are expected to expire in 2016.", "sentB": "With respect to PRX-110 AIR DNase, we face competition from Genentech Inc., a member of the Roche Group, which markets Pulmozyme , and from the producers of CFTR protein potentiation such as Vertex Pharmaceuticals Incorporated (Kalydeco and Orkambi ).", "type": 1, "words": ["<tag1>", "With", "respect", "to", "taliglucerase", "alfa,", "we", "have", "licensed", "the", "rights", "to", "two", "patents", "from", "Virginia", "Tech", "Intellectual", "Properties,", "Inc.,", "or", "Virginia", "Tech,", "that", "are", "expected", "to", "expire", "in", "2016.", "<tag2>", "With", "respect", "to", "PRX-110", "AIR", "DNase,", "we", "face", "competition", "from", "Genentech", "Inc.,", "a", "member", "of", "the", "Roche", "Group,", "which", "markets", "Pulmozyme", ",", "and", "from", "the", "producers", "of", "CFTR", "protein", "potentiation", "such", "as", "Vertex", "Pharmaceuticals", "Incorporated", "(Kalydeco", "and", "Orkambi", ").", "<tag3>"], "wordsA": ["With", "respect", "to", "taliglucerase", "alfa,", "we", "have", "licensed", "the", "rights", "to", "two", "patents", "from", "Virginia", "Tech", "Intellectual", "Properties,", "Inc.,", "or", "Virginia", "Tech,", "that", "are", "expected", "to", "expire", "in", "2016."], "wordsB": ["With", "respect", "to", "PRX-110", "AIR", "DNase,", "we", "face", "competition", "from", "Genentech", "Inc.,", "a", "member", "of", "the", "Roche", "Group,", "which", "markets", "Pulmozyme", ",", "and", "from", "the", "producers", "of", "CFTR", "protein", "potentiation", "such", "as", "Vertex", "Pharmaceuticals", "Incorporated", "(Kalydeco", "and", "Orkambi", ")."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_16_item1_p77_s2", "idA": "1006281_15_item1_p172_s1", "sentA": "Assuming that the clinical data support the product s safety and effectiveness for its intended use, a new drug application, or NDA, is submitted to the FDA for review.", "sentB": "Mean values for Cmax, and AUC were found to have briefly shifted at three and six months in antibody positive patients, where at 12 months, PK parameters returned to the high AUC levels observed at baseline, demonstrating that the antibody presence and its impact was transient, leading to full active dose availability for effective treatment.", "type": 1, "words": ["<tag1>", "Assuming", "that", "the", "clinical", "data", "support", "the", "product", "s", "safety", "and", "effectiveness", "for", "its", "intended", "use,", "a", "new", "drug", "application,", "or", "NDA,", "is", "submitted", "to", "the", "FDA", "for", "review.", "<tag2>", "Mean", "values", "for", "Cmax,", "and", "AUC", "were", "found", "to", "have", "briefly", "shifted", "at", "three", "and", "six", "months", "in", "antibody", "positive", "patients,", "where", "at", "12", "months,", "PK", "parameters", "returned", "to", "the", "high", "AUC", "levels", "observed", "at", "baseline,", "demonstrating", "that", "the", "antibody", "presence", "and", "its", "impact", "was", "transient,", "leading", "to", "full", "active", "dose", "availability", "for", "effective", "treatment.", "<tag3>"], "wordsA": ["Assuming", "that", "the", "clinical", "data", "support", "the", "product", "s", "safety", "and", "effectiveness", "for", "its", "intended", "use,", "a", "new", "drug", "application,", "or", "NDA,", "is", "submitted", "to", "the", "FDA", "for", "review."], "wordsB": ["Mean", "values", "for", "Cmax,", "and", "AUC", "were", "found", "to", "have", "briefly", "shifted", "at", "three", "and", "six", "months", "in", "antibody", "positive", "patients,", "where", "at", "12", "months,", "PK", "parameters", "returned", "to", "the", "high", "AUC", "levels", "observed", "at", "baseline,", "demonstrating", "that", "the", "antibody", "presence", "and", "its", "impact", "was", "transient,", "leading", "to", "full", "active", "dose", "availability", "for", "effective", "treatment."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_16_item1_p98_s2", "idA": "1006281_15_item1_p184_s1", "sentA": "Authorizations are granted after the assessment of quality, safety and efficacy by the respective health authorities.", "sentB": "The study will evaluate two different doses for safety and tolerability; pharmacokinetics; and efficacy parameters (vs. baseline): Mayo score, rectal bleeding, hHistopathological improvement (Geboes), hs-CRP levels, and fecal calprotectin level .", "type": 1, "words": ["<tag1>", "Authorizations", "are", "granted", "after", "the", "assessment", "of", "quality,", "safety", "and", "efficacy", "by", "the", "respective", "health", "authorities.", "<tag2>", "The", "study", "will", "evaluate", "two", "different", "doses", "for", "safety", "and", "tolerability;", "pharmacokinetics;", "and", "efficacy", "parameters", "(vs.", "baseline):", "Mayo", "score,", "rectal", "bleeding,", "hHistopathological", "improvement", "(Geboes),", "hs-CRP", "levels,", "and", "fecal", "calprotectin", "level", ".", "<tag3>"], "wordsA": ["Authorizations", "are", "granted", "after", "the", "assessment", "of", "quality,", "safety", "and", "efficacy", "by", "the", "respective", "health", "authorities."], "wordsB": ["The", "study", "will", "evaluate", "two", "different", "doses", "for", "safety", "and", "tolerability;", "pharmacokinetics;", "and", "efficacy", "parameters", "(vs.", "baseline):", "Mayo", "score,", "rectal", "bleeding,", "hHistopathological", "improvement", "(Geboes),", "hs-CRP", "levels,", "and", "fecal", "calprotectin", "level", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_16_item1_p82_s3", "idA": "1006281_15_item1_p20_s0", "sentA": "PRX-102 for the Treatment of Fabry disease .", "sentB": "Interim results from this head-to-head trial will also provide supportive safety data for the BLA submission.", "type": 1, "words": ["<tag1>", "PRX-102", "for", "the", "Treatment", "of", "Fabry", "disease", ".", "<tag2>", "Interim", "results", "from", "this", "head-to-head", "trial", "will", "also", "provide", "supportive", "safety", "data", "for", "the", "BLA", "submission.", "<tag3>"], "wordsA": ["PRX-102", "for", "the", "Treatment", "of", "Fabry", "disease", "."], "wordsB": ["Interim", "results", "from", "this", "head-to-head", "trial", "will", "also", "provide", "supportive", "safety", "data", "for", "the", "BLA", "submission."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_16_item1_p79_s4", "idA": "1006281_15_item1_p211_s1", "sentA": "No assurance can be made that approval to any such transfer, if requested, will be granted.", "sentB": "The primary endpoint will be gastrointestinal symptoms, with key secondary endpoints including renal function.", "type": 1, "words": ["<tag1>", "No", "assurance", "can", "be", "made", "that", "approval", "to", "any", "such", "transfer,", "if", "requested,", "will", "be", "granted.", "<tag2>", "The", "primary", "endpoint", "will", "be", "gastrointestinal", "symptoms,", "with", "key", "secondary", "endpoints", "including", "renal", "function.", "<tag3>"], "wordsA": ["No", "assurance", "can", "be", "made", "that", "approval", "to", "any", "such", "transfer,", "if", "requested,", "will", "be", "granted."], "wordsB": ["The", "primary", "endpoint", "will", "be", "gastrointestinal", "symptoms,", "with", "key", "secondary", "endpoints", "including", "renal", "function."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_16_item1_p89_s2", "idA": "1006281_15_item1_p211_s1", "sentA": "No assurance can be made that approval to any such transfer, if requested, will be granted.", "sentB": "The study will be designed to involve once daily inhalations with an eight-week study duration.", "type": 1, "words": ["<tag1>", "No", "assurance", "can", "be", "made", "that", "approval", "to", "any", "such", "transfer,", "if", "requested,", "will", "be", "granted.", "<tag2>", "The", "study", "will", "be", "designed", "to", "involve", "once", "daily", "inhalations", "with", "an", "eight-week", "study", "duration.", "<tag3>"], "wordsA": ["No", "assurance", "can", "be", "made", "that", "approval", "to", "any", "such", "transfer,", "if", "requested,", "will", "be", "granted."], "wordsB": ["The", "study", "will", "be", "designed", "to", "involve", "once", "daily", "inhalations", "with", "an", "eight-week", "study", "duration."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_16_item1_p98_s1", "idA": "1006281_15_item1_p211_s1", "sentA": "No assurance can be made that approval to any such transfer, if requested, will be granted.", "sentB": "The study will be designed to involve once daily administrations with an eight-week treatment duration.", "type": 1, "words": ["<tag1>", "No", "assurance", "can", "be", "made", "that", "approval", "to", "any", "such", "transfer,", "if", "requested,", "will", "be", "granted.", "<tag2>", "The", "study", "will", "be", "designed", "to", "involve", "once", "daily", "administrations", "with", "an", "eight-week", "treatment", "duration.", "<tag3>"], "wordsA": ["No", "assurance", "can", "be", "made", "that", "approval", "to", "any", "such", "transfer,", "if", "requested,", "will", "be", "granted."], "wordsB": ["The", "study", "will", "be", "designed", "to", "involve", "once", "daily", "administrations", "with", "an", "eight-week", "treatment", "duration."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_16_item1_p97_s2", "idA": "1006281_15_item1_p21_s1", "sentA": "Oral anti-TNF represents a novel mode of administering a recombinant anti-TNF protein.", "sentB": "The study consisted of 15 healthy volunteers divided into three dosing cohorts, equivalent to 2mg, 8mg or 16mg Tumor Necrosis Factor receptor-Fc fusion protein.", "type": 1, "words": ["<tag1>", "Oral", "anti-TNF", "represents", "a", "novel", "mode", "of", "administering", "a", "recombinant", "anti-TNF", "protein.", "<tag2>", "The", "study", "consisted", "of", "15", "healthy", "volunteers", "divided", "into", "three", "dosing", "cohorts,", "equivalent", "to", "2mg,", "8mg", "or", "16mg", "Tumor", "Necrosis", "Factor", "receptor-Fc", "fusion", "protein.", "<tag3>"], "wordsA": ["Oral", "anti-TNF", "represents", "a", "novel", "mode", "of", "administering", "a", "recombinant", "anti-TNF", "protein."], "wordsB": ["The", "study", "consisted", "of", "15", "healthy", "volunteers", "divided", "into", "three", "dosing", "cohorts,", "equivalent", "to", "2mg,", "8mg", "or", "16mg", "Tumor", "Necrosis", "Factor", "receptor-Fc", "fusion", "protein."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_16_item1_p77_s1", "idA": "1006281_15_item1_p226_s3", "sentA": "See Risk Factors We depend upon key employees and consultants in a competitive market for skilled personnel.", "sentB": "This resulted in low incidence of antibody formation with low titers in general, and moreover, in antibody positive patients it resulted in a transient and reversible shift of overall drug availability.", "type": 1, "words": ["<tag1>", "See", "Risk", "Factors", "We", "depend", "upon", "key", "employees", "and", "consultants", "in", "a", "competitive", "market", "for", "skilled", "personnel.", "<tag2>", "This", "resulted", "in", "low", "incidence", "of", "antibody", "formation", "with", "low", "titers", "in", "general,", "and", "moreover,", "in", "antibody", "positive", "patients", "it", "resulted", "in", "a", "transient", "and", "reversible", "shift", "of", "overall", "drug", "availability.", "<tag3>"], "wordsA": ["See", "Risk", "Factors", "We", "depend", "upon", "key", "employees", "and", "consultants", "in", "a", "competitive", "market", "for", "skilled", "personnel."], "wordsB": ["This", "resulted", "in", "low", "incidence", "of", "antibody", "formation", "with", "low", "titers", "in", "general,", "and", "moreover,", "in", "antibody", "positive", "patients", "it", "resulted", "in", "a", "transient", "and", "reversible", "shift", "of", "overall", "drug", "availability."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_16_item1_p82_s1", "idA": "1006281_15_item1_p24_s0", "sentA": "The initial clinical data generated for this compound in pre-clinical and clinical trials is promising.", "sentB": "The primary endpoint for this head-to-head trial will be an improvement in eGFR.", "type": 1, "words": ["<tag1>", "The", "initial", "clinical", "data", "generated", "for", "this", "compound", "in", "pre-clinical", "and", "clinical", "trials", "is", "promising.", "<tag2>", "The", "primary", "endpoint", "for", "this", "head-to-head", "trial", "will", "be", "an", "improvement", "in", "eGFR.", "<tag3>"], "wordsA": ["The", "initial", "clinical", "data", "generated", "for", "this", "compound", "in", "pre-clinical", "and", "clinical", "trials", "is", "promising."], "wordsB": ["The", "primary", "endpoint", "for", "this", "head-to-head", "trial", "will", "be", "an", "improvement", "in", "eGFR."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_16_item1_p95_s2", "idA": "1006281_15_item1_p34_s2", "sentA": "Furthermore, the current FDA and other procedures only ensure screening for scientifically identified, known viruses.", "sentB": "Furthermore, the drug was shown to alleviate liver damage and reduce liver necrosis and liver enzymes, ALT and AST, thus leading to an improvement in liver biopsies.", "type": 1, "words": ["<tag1>", "Furthermore,", "the", "current", "FDA", "and", "other", "procedures", "only", "ensure", "screening", "for", "scientifically", "identified,", "known", "viruses.", "<tag2>", "Furthermore,", "the", "drug", "was", "shown", "to", "alleviate", "liver", "damage", "and", "reduce", "liver", "necrosis", "and", "liver", "enzymes,", "ALT", "and", "AST,", "thus", "leading", "to", "an", "improvement", "in", "liver", "biopsies.", "<tag3>"], "wordsA": ["Furthermore,", "the", "current", "FDA", "and", "other", "procedures", "only", "ensure", "screening", "for", "scientifically", "identified,", "known", "viruses."], "wordsB": ["Furthermore,", "the", "drug", "was", "shown", "to", "alleviate", "liver", "damage", "and", "reduce", "liver", "necrosis", "and", "liver", "enzymes,", "ALT", "and", "AST,", "thus", "leading", "to", "an", "improvement", "in", "liver", "biopsies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_16_item1_p141_s0", "idA": "1006281_15_item1_p68_s0", "sentA": "According to public reports by Sanofi, consolidated sales of Cerezyme during the year ended December 31, 2014 were 715 million (or approximately $865 million), a growth of approximately 8% compared to the same period in 2013.", "sentB": "American Association for Cancer Research, 2013 Award for Outstanding Achievement in Chemistry in Cancer Research.", "type": 1, "words": ["<tag1>", "According", "to", "public", "reports", "by", "Sanofi,", "consolidated", "sales", "of", "Cerezyme", "during", "the", "year", "ended", "December", "31,", "2014", "were", "715", "million", "(or", "approximately", "$865", "million),", "a", "growth", "of", "approximately", "8%", "compared", "to", "the", "same", "period", "in", "2013.", "<tag2>", "American", "Association", "for", "Cancer", "Research,", "2013", "Award", "for", "Outstanding", "Achievement", "in", "Chemistry", "in", "Cancer", "Research.", "<tag3>"], "wordsA": ["According", "to", "public", "reports", "by", "Sanofi,", "consolidated", "sales", "of", "Cerezyme", "during", "the", "year", "ended", "December", "31,", "2014", "were", "715", "million", "(or", "approximately", "$865", "million),", "a", "growth", "of", "approximately", "8%", "compared", "to", "the", "same", "period", "in", "2013."], "wordsB": ["American", "Association", "for", "Cancer", "Research,", "2013", "Award", "for", "Outstanding", "Achievement", "in", "Chemistry", "in", "Cancer", "Research."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_16_item1_p81_s0", "idA": "1006281_15_item1_p68_s0", "sentA": "According to public reports by Sanofi, consolidated sales of Cerezyme during the year ended December 31, 2014 were 715 million (or approximately $865 million), a growth of approximately 8% compared to the same period in 2013.", "sentB": "According to the FDA, during a recent ERT shortage, patients who reduced or discontinued ERT dosing developed worsening of GI signs and symptoms within a few weeks to months.", "type": 1, "words": ["<tag1>", "According", "to", "public", "reports", "by", "Sanofi,", "consolidated", "sales", "of", "Cerezyme", "during", "the", "year", "ended", "December", "31,", "2014", "were", "715", "million", "(or", "approximately", "$865", "million),", "a", "growth", "of", "approximately", "8%", "compared", "to", "the", "same", "period", "in", "2013.", "<tag2>", "According", "to", "the", "FDA,", "during", "a", "recent", "ERT", "shortage,", "patients", "who", "reduced", "or", "discontinued", "ERT", "dosing", "developed", "worsening", "of", "GI", "signs", "and", "symptoms", "within", "a", "few", "weeks", "to", "months.", "<tag3>"], "wordsA": ["According", "to", "public", "reports", "by", "Sanofi,", "consolidated", "sales", "of", "Cerezyme", "during", "the", "year", "ended", "December", "31,", "2014", "were", "715", "million", "(or", "approximately", "$865", "million),", "a", "growth", "of", "approximately", "8%", "compared", "to", "the", "same", "period", "in", "2013."], "wordsB": ["According", "to", "the", "FDA,", "during", "a", "recent", "ERT", "shortage,", "patients", "who", "reduced", "or", "discontinued", "ERT", "dosing", "developed", "worsening", "of", "GI", "signs", "and", "symptoms", "within", "a", "few", "weeks", "to", "months."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_16_item1_p4_s2", "idA": "1006281_15_item1_p6_s1", "sentA": "We granted Pfizer an exclusive, worldwide license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but we retained those rights in Israel, and later in Brazil.", "sentB": "The Amended Pfizer Agreement eliminates Pfizer s entitlement to annual payments of up to $12.5 million in relation to commercialization of Elelyso in Brazil.", "type": 1, "words": ["<tag1>", "We", "granted", "Pfizer", "an", "exclusive,", "worldwide", "license", "to", "develop", "and", "commercialize", "taliglucerase", "alfa", "under", "the", "Pfizer", "Agreement,", "but", "we", "retained", "those", "rights", "in", "Israel,", "and", "later", "in", "Brazil.", "<tag2>", "The", "Amended", "Pfizer", "Agreement", "eliminates", "Pfizer", "s", "entitlement", "to", "annual", "payments", "of", "up", "to", "$12.5", "million", "in", "relation", "to", "commercialization", "of", "Elelyso", "in", "Brazil.", "<tag3>"], "wordsA": ["We", "granted", "Pfizer", "an", "exclusive,", "worldwide", "license", "to", "develop", "and", "commercialize", "taliglucerase", "alfa", "under", "the", "Pfizer", "Agreement,", "but", "we", "retained", "those", "rights", "in", "Israel,", "and", "later", "in", "Brazil."], "wordsB": ["The", "Amended", "Pfizer", "Agreement", "eliminates", "Pfizer", "s", "entitlement", "to", "annual", "payments", "of", "up", "to", "$12.5", "million", "in", "relation", "to", "commercialization", "of", "Elelyso", "in", "Brazil."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_16_item1_p76_s1", "idA": "1006281_15_item1_p83_s3", "sentA": "Each patient receives intravenous infusions of PRX-102 every two weeks for 12 weeks, with a six-month efficacy follow up period.", "sentB": "After dosing with 0.2mg/kg of PRX-102 for 12 months, a majority of the patients (4/6) experienced a stabilization or improvement in kidney function; a reversal of the decline shown by annualized eGFR slope was observed.", "type": 1, "words": ["<tag1>", "Each", "patient", "receives", "intravenous", "infusions", "of", "PRX-102", "every", "two", "weeks", "for", "12", "weeks,", "with", "a", "six-month", "efficacy", "follow", "up", "period.", "<tag2>", "After", "dosing", "with", "0.2mg/kg", "of", "PRX-102", "for", "12", "months,", "a", "majority", "of", "the", "patients", "(4/6)", "experienced", "a", "stabilization", "or", "improvement", "in", "kidney", "function;", "a", "reversal", "of", "the", "decline", "shown", "by", "annualized", "eGFR", "slope", "was", "observed.", "<tag3>"], "wordsA": ["Each", "patient", "receives", "intravenous", "infusions", "of", "PRX-102", "every", "two", "weeks", "for", "12", "weeks,", "with", "a", "six-month", "efficacy", "follow", "up", "period."], "wordsB": ["After", "dosing", "with", "0.2mg/kg", "of", "PRX-102", "for", "12", "months,", "a", "majority", "of", "the", "patients", "(4/6)", "experienced", "a", "stabilization", "or", "improvement", "in", "kidney", "function;", "a", "reversal", "of", "the", "decline", "shown", "by", "annualized", "eGFR", "slope", "was", "observed."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_16_item1_p89_s3", "idA": "1006281_15_item1_p87_s2", "sentA": "Absolute change from baseline was -4.5, -1.2 and -3.2, respectively.", "sentB": "The study will evaluate safety and tolerability; pharmacokinetics; efficacy parameters: change from baseline in FEV1 (Forced Expiratory Volume in One Second) and FVC (Forced Vital Capacity); DNA parameters in sputum; and sputum rheology parameters.", "type": 1, "words": ["<tag1>", "Absolute", "change", "from", "baseline", "was", "-4.5,", "-1.2", "and", "-3.2,", "respectively.", "<tag2>", "The", "study", "will", "evaluate", "safety", "and", "tolerability;", "pharmacokinetics;", "efficacy", "parameters:", "change", "from", "baseline", "in", "FEV1", "(Forced", "Expiratory", "Volume", "in", "One", "Second)", "and", "FVC", "(Forced", "Vital", "Capacity);", "DNA", "parameters", "in", "sputum;", "and", "sputum", "rheology", "parameters.", "<tag3>"], "wordsA": ["Absolute", "change", "from", "baseline", "was", "-4.5,", "-1.2", "and", "-3.2,", "respectively."], "wordsB": ["The", "study", "will", "evaluate", "safety", "and", "tolerability;", "pharmacokinetics;", "efficacy", "parameters:", "change", "from", "baseline", "in", "FEV1", "(Forced", "Expiratory", "Volume", "in", "One", "Second)", "and", "FVC", "(Forced", "Vital", "Capacity);", "DNA", "parameters", "in", "sputum;", "and", "sputum", "rheology", "parameters."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_16_item1_p77_s0", "idA": "1006281_15_item1_p95_s0", "sentA": "Six patients receiving the 0.2mg/kg dose and two patients receiving the 1m/kg dose were evaluated for antibody formation.", "sentB": "PRX-102 s unique and enhanced PK properties resulted in long half-life, high AUC and measured levels of enzyme found throughout the entire two weeks infusion intervals in all patients of the 0.2mg/kg cohort of the trial, potentially contributing to an immune tolerance phenomenon.", "type": 1, "words": ["<tag1>", "Six", "patients", "receiving", "the", "0.2mg/kg", "dose", "and", "two", "patients", "receiving", "the", "1m/kg", "dose", "were", "evaluated", "for", "antibody", "formation.", "<tag2>", "PRX-102", "s", "unique", "and", "enhanced", "PK", "properties", "resulted", "in", "long", "half-life,", "high", "AUC", "and", "measured", "levels", "of", "enzyme", "found", "throughout", "the", "entire", "two", "weeks", "infusion", "intervals", "in", "all", "patients", "of", "the", "0.2mg/kg", "cohort", "of", "the", "trial,", "potentially", "contributing", "to", "an", "immune", "tolerance", "phenomenon.", "<tag3>"], "wordsA": ["Six", "patients", "receiving", "the", "0.2mg/kg", "dose", "and", "two", "patients", "receiving", "the", "1m/kg", "dose", "were", "evaluated", "for", "antibody", "formation."], "wordsB": ["PRX-102", "s", "unique", "and", "enhanced", "PK", "properties", "resulted", "in", "long", "half-life,", "high", "AUC", "and", "measured", "levels", "of", "enzyme", "found", "throughout", "the", "entire", "two", "weeks", "infusion", "intervals", "in", "all", "patients", "of", "the", "0.2mg/kg", "cohort", "of", "the", "trial,", "potentially", "contributing", "to", "an", "immune", "tolerance", "phenomenon."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_17_item1_p81_s1", "idA": "1006281_16_item1_p114_s1", "sentA": "The patent is expected to expire in 2031.", "sentB": "At that time, 15 patients had been enrolled in, and were expected to complete, the study.", "type": 1, "words": ["<tag1>", "The", "patent", "is", "expected", "to", "expire", "in", "2031.", "<tag2>", "At", "that", "time,", "15", "patients", "had", "been", "enrolled", "in,", "and", "were", "expected", "to", "complete,", "the", "study.", "<tag3>"], "wordsA": ["The", "patent", "is", "expected", "to", "expire", "in", "2031."], "wordsB": ["At", "that", "time,", "15", "patients", "had", "been", "enrolled", "in,", "and", "were", "expected", "to", "complete,", "the", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_17_item1_p66_s0", "idA": "1006281_16_item1_p11_s3", "sentA": "It has demonstrated improved disease parameters in animal models and human sputum testing when compared to the currently marketed product.", "sentB": "Improvements or stabilization in efficacy parameters were demonstrated across all disease parameters.", "type": 1, "words": ["<tag1>", "It", "has", "demonstrated", "improved", "disease", "parameters", "in", "animal", "models", "and", "human", "sputum", "testing", "when", "compared", "to", "the", "currently", "marketed", "product.", "<tag2>", "Improvements", "or", "stabilization", "in", "efficacy", "parameters", "were", "demonstrated", "across", "all", "disease", "parameters.", "<tag3>"], "wordsA": ["It", "has", "demonstrated", "improved", "disease", "parameters", "in", "animal", "models", "and", "human", "sputum", "testing", "when", "compared", "to", "the", "currently", "marketed", "product."], "wordsB": ["Improvements", "or", "stabilization", "in", "efficacy", "parameters", "were", "demonstrated", "across", "all", "disease", "parameters."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_17_item1_p61_s1", "idA": "1006281_16_item1_p125_s3", "sentA": "In addition, we were obligated to make milestone payments equal to $150,000, in the aggregate, upon the achievement of certain milestones, which milestone payments have been satisfied.", "sentB": "In addition, to be included in the trial, patients need to have certain eGFR values and a meaningful decline in annualize eGFR slope.", "type": 1, "words": ["<tag1>", "In", "addition,", "we", "were", "obligated", "to", "make", "milestone", "payments", "equal", "to", "$150,000,", "in", "the", "aggregate,", "upon", "the", "achievement", "of", "certain", "milestones,", "which", "milestone", "payments", "have", "been", "satisfied.", "<tag2>", "In", "addition,", "to", "be", "included", "in", "the", "trial,", "patients", "need", "to", "have", "certain", "eGFR", "values", "and", "a", "meaningful", "decline", "in", "annualize", "eGFR", "slope.", "<tag3>"], "wordsA": ["In", "addition,", "we", "were", "obligated", "to", "make", "milestone", "payments", "equal", "to", "$150,000,", "in", "the", "aggregate,", "upon", "the", "achievement", "of", "certain", "milestones,", "which", "milestone", "payments", "have", "been", "satisfied."], "wordsB": ["In", "addition,", "to", "be", "included", "in", "the", "trial,", "patients", "need", "to", "have", "certain", "eGFR", "values", "and", "a", "meaningful", "decline", "in", "annualize", "eGFR", "slope."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_17_item1_p93_s2", "idA": "1006281_16_item1_p12_s6", "sentA": "If approved, oPRX-106 will be the first ever oral enzyme treatment.", "sentB": "Patients will be randomized to receive 2 mg or 8 mg of OPRX-106 administered orally, once daily, for eight weeks.", "type": 1, "words": ["<tag1>", "If", "approved,", "oPRX-106", "will", "be", "the", "first", "ever", "oral", "enzyme", "treatment.", "<tag2>", "Patients", "will", "be", "randomized", "to", "receive", "2", "mg", "or", "8", "mg", "of", "OPRX-106", "administered", "orally,", "once", "daily,", "for", "eight", "weeks.", "<tag3>"], "wordsA": ["If", "approved,", "oPRX-106", "will", "be", "the", "first", "ever", "oral", "enzyme", "treatment."], "wordsB": ["Patients", "will", "be", "randomized", "to", "receive", "2", "mg", "or", "8", "mg", "of", "OPRX-106", "administered", "orally,", "once", "daily,", "for", "eight", "weeks."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_17_item1_p99_s0", "idA": "1006281_16_item1_p132_s2", "sentA": "We have identified additional suppliers for most of the materials required for the production of our product candidates.", "sentB": "We issued as series of 7.5% convertible notes in December 2016, which are guaranteed by our subsidiaries and secured by perfected liens on all of our material assets, primarily consisting of our intellectual property assets, including a stock pledge of our foreign subsidiaries in favor of the holders of outstanding 7.5% convertible notes.", "type": 1, "words": ["<tag1>", "We", "have", "identified", "additional", "suppliers", "for", "most", "of", "the", "materials", "required", "for", "the", "production", "of", "our", "product", "candidates.", "<tag2>", "We", "issued", "as", "series", "of", "7.5%", "convertible", "notes", "in", "December", "2016,", "which", "are", "guaranteed", "by", "our", "subsidiaries", "and", "secured", "by", "perfected", "liens", "on", "all", "of", "our", "material", "assets,", "primarily", "consisting", "of", "our", "intellectual", "property", "assets,", "including", "a", "stock", "pledge", "of", "our", "foreign", "subsidiaries", "in", "favor", "of", "the", "holders", "of", "outstanding", "7.5%", "convertible", "notes.", "<tag3>"], "wordsA": ["We", "have", "identified", "additional", "suppliers", "for", "most", "of", "the", "materials", "required", "for", "the", "production", "of", "our", "product", "candidates."], "wordsB": ["We", "issued", "as", "series", "of", "7.5%", "convertible", "notes", "in", "December", "2016,", "which", "are", "guaranteed", "by", "our", "subsidiaries", "and", "secured", "by", "perfected", "liens", "on", "all", "of", "our", "material", "assets,", "primarily", "consisting", "of", "our", "intellectual", "property", "assets,", "including", "a", "stock", "pledge", "of", "our", "foreign", "subsidiaries", "in", "favor", "of", "the", "holders", "of", "outstanding", "7.5%", "convertible", "notes."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_17_item1_p80_s2", "idA": "1006281_16_item1_p135_s2", "sentA": "Replagal is available in the European Union.", "sentB": "Participation in the trial is preceded by a two-week washout period from Pulmozyme before treatment with alidornase alfa via inhalation.", "type": 1, "words": ["<tag1>", "Replagal", "is", "available", "in", "the", "European", "Union.", "<tag2>", "Participation", "in", "the", "trial", "is", "preceded", "by", "a", "two-week", "washout", "period", "from", "Pulmozyme", "before", "treatment", "with", "alidornase", "alfa", "via", "inhalation.", "<tag3>"], "wordsA": ["Replagal", "is", "available", "in", "the", "European", "Union."], "wordsB": ["Participation", "in", "the", "trial", "is", "preceded", "by", "a", "two-week", "washout", "period", "from", "Pulmozyme", "before", "treatment", "with", "alidornase", "alfa", "via", "inhalation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_17_item1_p92_s6", "idA": "1006281_16_item1_p138_s3", "sentA": "Other companies are developing alternate plant-based technologies, include, among others, iBio, Inc., Medicago Inc., and Greenovation Biotech GmbH, none of which are cell-based.", "sentB": "Fluorescence-activated cell sorting analysis (FACS) was performed using various antibodies for surface markers, and it was observed that all three dosages of OPRX-106 promoted the induction of various subsets of T cells, some of which are correlated with anti-inflammatory response.", "type": 1, "words": ["<tag1>", "Other", "companies", "are", "developing", "alternate", "plant-based", "technologies,", "include,", "among", "others,", "iBio,", "Inc.,", "Medicago", "Inc.,", "and", "Greenovation", "Biotech", "GmbH,", "none", "of", "which", "are", "cell-based.", "<tag2>", "Fluorescence-activated", "cell", "sorting", "analysis", "(FACS)", "was", "performed", "using", "various", "antibodies", "for", "surface", "markers,", "and", "it", "was", "observed", "that", "all", "three", "dosages", "of", "OPRX-106", "promoted", "the", "induction", "of", "various", "subsets", "of", "T", "cells,", "some", "of", "which", "are", "correlated", "with", "anti-inflammatory", "response.", "<tag3>"], "wordsA": ["Other", "companies", "are", "developing", "alternate", "plant-based", "technologies,", "include,", "among", "others,", "iBio,", "Inc.,", "Medicago", "Inc.,", "and", "Greenovation", "Biotech", "GmbH,", "none", "of", "which", "are", "cell-based."], "wordsB": ["Fluorescence-activated", "cell", "sorting", "analysis", "(FACS)", "was", "performed", "using", "various", "antibodies", "for", "surface", "markers,", "and", "it", "was", "observed", "that", "all", "three", "dosages", "of", "OPRX-106", "promoted", "the", "induction", "of", "various", "subsets", "of", "T", "cells,", "some", "of", "which", "are", "correlated", "with", "anti-inflammatory", "response."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_17_item1_p80_s4", "idA": "1006281_16_item1_p159_s1", "sentA": "Authorizations are granted after the assessment of quality, safety and efficacy by the respective health authorities.", "sentB": "Additional endpoints include safety and tolerability, immunogenicity and pharmacokinetic data.", "type": 1, "words": ["<tag1>", "Authorizations", "are", "granted", "after", "the", "assessment", "of", "quality,", "safety", "and", "efficacy", "by", "the", "respective", "health", "authorities.", "<tag2>", "Additional", "endpoints", "include", "safety", "and", "tolerability,", "immunogenicity", "and", "pharmacokinetic", "data.", "<tag3>"], "wordsA": ["Authorizations", "are", "granted", "after", "the", "assessment", "of", "quality,", "safety", "and", "efficacy", "by", "the", "respective", "health", "authorities."], "wordsB": ["Additional", "endpoints", "include", "safety", "and", "tolerability,", "immunogenicity", "and", "pharmacokinetic", "data."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_17_item1_p8_s2", "idA": "1006281_16_item1_p205_s1", "sentA": "Such copies can be retrieved electronically through the TASE s internet messaging system (www.maya.tase.co.il) and through the MAGNA distribution site of the Israeli Securities Authority (www.magna.isa.gov.il).", "sentB": "Shipments are to start in mid-2017 and continue through the end of the year, in increasing volumes.", "type": 1, "words": ["<tag1>", "Such", "copies", "can", "be", "retrieved", "electronically", "through", "the", "TASE", "s", "internet", "messaging", "system", "(www.maya.tase.co.il)", "and", "through", "the", "MAGNA", "distribution", "site", "of", "the", "Israeli", "Securities", "Authority", "(www.magna.isa.gov.il).", "<tag2>", "Shipments", "are", "to", "start", "in", "mid-2017", "and", "continue", "through", "the", "end", "of", "the", "year,", "in", "increasing", "volumes.", "<tag3>"], "wordsA": ["Such", "copies", "can", "be", "retrieved", "electronically", "through", "the", "TASE", "s", "internet", "messaging", "system", "(www.maya.tase.co.il)", "and", "through", "the", "MAGNA", "distribution", "site", "of", "the", "Israeli", "Securities", "Authority", "(www.magna.isa.gov.il)."], "wordsB": ["Shipments", "are", "to", "start", "in", "mid-2017", "and", "continue", "through", "the", "end", "of", "the", "year,", "in", "increasing", "volumes."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_17_item1_p95_s2", "idA": "1006281_16_item1_p205_s1", "sentA": "Such copies can be retrieved electronically through the TASE s internet messaging system (www.maya.tase.co.il) and through the MAGNA distribution site of the Israeli Securities Authority (www.magna.isa.gov.il).", "sentB": "Shipments are to start in mid-2017 and continue through the end of the year, in increasing volumes.", "type": 1, "words": ["<tag1>", "Such", "copies", "can", "be", "retrieved", "electronically", "through", "the", "TASE", "s", "internet", "messaging", "system", "(www.maya.tase.co.il)", "and", "through", "the", "MAGNA", "distribution", "site", "of", "the", "Israeli", "Securities", "Authority", "(www.magna.isa.gov.il).", "<tag2>", "Shipments", "are", "to", "start", "in", "mid-2017", "and", "continue", "through", "the", "end", "of", "the", "year,", "in", "increasing", "volumes.", "<tag3>"], "wordsA": ["Such", "copies", "can", "be", "retrieved", "electronically", "through", "the", "TASE", "s", "internet", "messaging", "system", "(www.maya.tase.co.il)", "and", "through", "the", "MAGNA", "distribution", "site", "of", "the", "Israeli", "Securities", "Authority", "(www.magna.isa.gov.il)."], "wordsB": ["Shipments", "are", "to", "start", "in", "mid-2017", "and", "continue", "through", "the", "end", "of", "the", "year,", "in", "increasing", "volumes."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_17_item1_p83_s2", "idA": "1006281_16_item1_p2_s1", "sentA": "Subsequently, taliglucerase alfa was approved for marketing by the regulatory authorities of other countries.", "sentB": "This data provides further supportive evidence of improved lung function after treatment with alidornase alfa, as demonstrated by the increase in ppFEV1.", "type": 1, "words": ["<tag1>", "Subsequently,", "taliglucerase", "alfa", "was", "approved", "for", "marketing", "by", "the", "regulatory", "authorities", "of", "other", "countries.", "<tag2>", "This", "data", "provides", "further", "supportive", "evidence", "of", "improved", "lung", "function", "after", "treatment", "with", "alidornase", "alfa,", "as", "demonstrated", "by", "the", "increase", "in", "ppFEV1.", "<tag3>"], "wordsA": ["Subsequently,", "taliglucerase", "alfa", "was", "approved", "for", "marketing", "by", "the", "regulatory", "authorities", "of", "other", "countries."], "wordsB": ["This", "data", "provides", "further", "supportive", "evidence", "of", "improved", "lung", "function", "after", "treatment", "with", "alidornase", "alfa,", "as", "demonstrated", "by", "the", "increase", "in", "ppFEV1."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_17_item1_p86_s1", "idA": "1006281_16_item1_p43_s3", "sentA": "This system also reduces ongoing production and monitoring costs typically associated with mammalian cell-based expression technologies.", "sentB": "Immune-mediated inflammatory disorders can cause organ damage, and are associated with increased morbidity.", "type": 1, "words": ["<tag1>", "This", "system", "also", "reduces", "ongoing", "production", "and", "monitoring", "costs", "typically", "associated", "with", "mammalian", "cell-based", "expression", "technologies.", "<tag2>", "Immune-mediated", "inflammatory", "disorders", "can", "cause", "organ", "damage,", "and", "are", "associated", "with", "increased", "morbidity.", "<tag3>"], "wordsA": ["This", "system", "also", "reduces", "ongoing", "production", "and", "monitoring", "costs", "typically", "associated", "with", "mammalian", "cell-based", "expression", "technologies."], "wordsB": ["Immune-mediated", "inflammatory", "disorders", "can", "cause", "organ", "damage,", "and", "are", "associated", "with", "increased", "morbidity."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_17_item1_p71_s2", "idA": "1006281_16_item1_p56_s0", "sentA": "We believe that the treatment of Fabry disease is a specialty clinical niche with the potential for high growth as there is a significant unmet medical need for Fabry disease treatments.", "sentB": "This unique enzyme parameter of PRX-102 demonstrated the potential for reduced immunogenicity and induction of immune tolerance.", "type": 1, "words": ["<tag1>", "We", "believe", "that", "the", "treatment", "of", "Fabry", "disease", "is", "a", "specialty", "clinical", "niche", "with", "the", "potential", "for", "high", "growth", "as", "there", "is", "a", "significant", "unmet", "medical", "need", "for", "Fabry", "disease", "treatments.", "<tag2>", "This", "unique", "enzyme", "parameter", "of", "PRX-102", "demonstrated", "the", "potential", "for", "reduced", "immunogenicity", "and", "induction", "of", "immune", "tolerance.", "<tag3>"], "wordsA": ["We", "believe", "that", "the", "treatment", "of", "Fabry", "disease", "is", "a", "specialty", "clinical", "niche", "with", "the", "potential", "for", "high", "growth", "as", "there", "is", "a", "significant", "unmet", "medical", "need", "for", "Fabry", "disease", "treatments."], "wordsB": ["This", "unique", "enzyme", "parameter", "of", "PRX-102", "demonstrated", "the", "potential", "for", "reduced", "immunogenicity", "and", "induction", "of", "immune", "tolerance."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_17_item1_p65_s0", "idA": "1006281_16_item1_p60_s2", "sentA": "Sanofi reported 592 million (approximately $643 million) in worldwide sales of Fabrazyme in 2015.", "sentB": "Phase I/II Clinical Data; Efficacy Results:", "type": 1, "words": ["<tag1>", "Sanofi", "reported", "592", "million", "(approximately", "$643", "million)", "in", "worldwide", "sales", "of", "Fabrazyme", "in", "2015.", "<tag2>", "Phase", "I/II", "Clinical", "Data;", "Efficacy", "Results:", "<tag3>"], "wordsA": ["Sanofi", "reported", "592", "million", "(approximately", "$643", "million)", "in", "worldwide", "sales", "of", "Fabrazyme", "in", "2015."], "wordsB": ["Phase", "I/II", "Clinical", "Data;", "Efficacy", "Results:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_17_item1_p87_s1", "idA": "1006281_16_item1_p60_s2", "sentA": "Sanofi reported 592 million (approximately $643 million) in worldwide sales of Fabrazyme in 2015.", "sentB": "Sales of anti-TNF drugs exceeded $30 billion annually.", "type": 1, "words": ["<tag1>", "Sanofi", "reported", "592", "million", "(approximately", "$643", "million)", "in", "worldwide", "sales", "of", "Fabrazyme", "in", "2015.", "<tag2>", "Sales", "of", "anti-TNF", "drugs", "exceeded", "$30", "billion", "annually.", "<tag3>"], "wordsA": ["Sanofi", "reported", "592", "million", "(approximately", "$643", "million)", "in", "worldwide", "sales", "of", "Fabrazyme", "in", "2015."], "wordsB": ["Sales", "of", "anti-TNF", "drugs", "exceeded", "$30", "billion", "annually."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_17_item1_p82_s0", "idA": "1006281_16_item1_p61_s0", "sentA": "The other approved drug for the treatment of Fabry disease in the European Union is Replagal, which is marketed by Shire.", "sentB": "The initial primary efficacy result shows that alidornase alfa improves lung function as demonstrated by a mean absolute increase in the percent predicted forced expiratory volume in one second (ppFEV1) of 4.1 points from baseline and 3.1 points from last treatment of Pulmozyme.", "type": 1, "words": ["<tag1>", "The", "other", "approved", "drug", "for", "the", "treatment", "of", "Fabry", "disease", "in", "the", "European", "Union", "is", "Replagal,", "which", "is", "marketed", "by", "Shire.", "<tag2>", "The", "initial", "primary", "efficacy", "result", "shows", "that", "alidornase", "alfa", "improves", "lung", "function", "as", "demonstrated", "by", "a", "mean", "absolute", "increase", "in", "the", "percent", "predicted", "forced", "expiratory", "volume", "in", "one", "second", "(ppFEV1)", "of", "4.1", "points", "from", "baseline", "and", "3.1", "points", "from", "last", "treatment", "of", "Pulmozyme.", "<tag3>"], "wordsA": ["The", "other", "approved", "drug", "for", "the", "treatment", "of", "Fabry", "disease", "in", "the", "European", "Union", "is", "Replagal,", "which", "is", "marketed", "by", "Shire."], "wordsB": ["The", "initial", "primary", "efficacy", "result", "shows", "that", "alidornase", "alfa", "improves", "lung", "function", "as", "demonstrated", "by", "a", "mean", "absolute", "increase", "in", "the", "percent", "predicted", "forced", "expiratory", "volume", "in", "one", "second", "(ppFEV1)", "of", "4.1", "points", "from", "baseline", "and", "3.1", "points", "from", "last", "treatment", "of", "Pulmozyme."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_17_item1_p60_s1", "idA": "1006281_16_item1_p62_s0", "sentA": "In February 2015, we announced the completion of enrollment in our phase I/II clinical trial in adult Fabry patients.", "sentB": "The sites are recruiting adult symptomatic Fabry patients with plasma and/or leucocyte alpha galactosidase activity (by activity assay) less than 30% mean normal levels.", "type": 1, "words": ["<tag1>", "In", "February", "2015,", "we", "announced", "the", "completion", "of", "enrollment", "in", "our", "phase", "I/II", "clinical", "trial", "in", "adult", "Fabry", "patients.", "<tag2>", "The", "sites", "are", "recruiting", "adult", "symptomatic", "Fabry", "patients", "with", "plasma", "and/or", "leucocyte", "alpha", "galactosidase", "activity", "(by", "activity", "assay)", "less", "than", "30%", "mean", "normal", "levels.", "<tag3>"], "wordsA": ["In", "February", "2015,", "we", "announced", "the", "completion", "of", "enrollment", "in", "our", "phase", "I/II", "clinical", "trial", "in", "adult", "Fabry", "patients."], "wordsB": ["The", "sites", "are", "recruiting", "adult", "symptomatic", "Fabry", "patients", "with", "plasma", "and/or", "leucocyte", "alpha", "galactosidase", "activity", "(by", "activity", "assay)", "less", "than", "30%", "mean", "normal", "levels."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_17_item1_p67_s2", "idA": "1006281_16_item1_p62_s0", "sentA": "In February 2015, we announced the completion of enrollment in our phase I/II clinical trial in adult Fabry patients.", "sentB": "The eGFR slope for Classic Fabry patients (n=10) was -1.8 (BL 82.4-156.3).", "type": 1, "words": ["<tag1>", "In", "February", "2015,", "we", "announced", "the", "completion", "of", "enrollment", "in", "our", "phase", "I/II", "clinical", "trial", "in", "adult", "Fabry", "patients.", "<tag2>", "The", "eGFR", "slope", "for", "Classic", "Fabry", "patients", "(n=10)", "was", "-1.8", "(BL", "82.4-156.3).", "<tag3>"], "wordsA": ["In", "February", "2015,", "we", "announced", "the", "completion", "of", "enrollment", "in", "our", "phase", "I/II", "clinical", "trial", "in", "adult", "Fabry", "patients."], "wordsB": ["The", "eGFR", "slope", "for", "Classic", "Fabry", "patients", "(n=10)", "was", "-1.8", "(BL", "82.4-156.3)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_17_item1_p67_s6", "idA": "1006281_16_item1_p71_s0", "sentA": "Reductions of plasma Lyso-Gb3 and plasma Gb3 concentrations were also observed.", "sentB": "Similarly, levels after one year of treatment, average reductions in plasma Gb3 were 22.2% in all patients, and 33.3% in Classic patients.", "type": 1, "words": ["<tag1>", "Reductions", "of", "plasma", "Lyso-Gb3", "and", "plasma", "Gb3", "concentrations", "were", "also", "observed.", "<tag2>", "Similarly,", "levels", "after", "one", "year", "of", "treatment,", "average", "reductions", "in", "plasma", "Gb3", "were", "22.2%", "in", "all", "patients,", "and", "33.3%", "in", "Classic", "patients.", "<tag3>"], "wordsA": ["Reductions", "of", "plasma", "Lyso-Gb3", "and", "plasma", "Gb3", "concentrations", "were", "also", "observed."], "wordsB": ["Similarly,", "levels", "after", "one", "year", "of", "treatment,", "average", "reductions", "in", "plasma", "Gb3", "were", "22.2%", "in", "all", "patients,", "and", "33.3%", "in", "Classic", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_17_item1_p67_s1", "idA": "1006281_16_item1_p72_s0", "sentA": "Furthermore, all patients had stable cardiac function after only six months, as measured by left ventricular mass (LVM), left ventricular mass index (LVMI) and ejection fraction (EF).", "sentB": "The eGFR slope for all patients (n=16) using CKD-EPI was -2.9 (BL-77.7-156.3).", "type": 1, "words": ["<tag1>", "Furthermore,", "all", "patients", "had", "stable", "cardiac", "function", "after", "only", "six", "months,", "as", "measured", "by", "left", "ventricular", "mass", "(LVM),", "left", "ventricular", "mass", "index", "(LVMI)", "and", "ejection", "fraction", "(EF).", "<tag2>", "The", "eGFR", "slope", "for", "all", "patients", "(n=16)", "using", "CKD-EPI", "was", "-2.9", "(BL-77.7-156.3).", "<tag3>"], "wordsA": ["Furthermore,", "all", "patients", "had", "stable", "cardiac", "function", "after", "only", "six", "months,", "as", "measured", "by", "left", "ventricular", "mass", "(LVM),", "left", "ventricular", "mass", "index", "(LVMI)", "and", "ejection", "fraction", "(EF)."], "wordsB": ["The", "eGFR", "slope", "for", "all", "patients", "(n=16)", "using", "CKD-EPI", "was", "-2.9", "(BL-77.7-156.3)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_17_item1_p69_s1", "idA": "1006281_16_item1_p76_s0", "sentA": "On average, patients that participated in the 0.2mg/kg cohort of the PRX-102 phase I/II trial exhibited stability in kidney function with favorable trends shown, as measured by estimated Glomerular filtration rate (eGFR).", "sentB": "Patients in the 1 mg/kg dosing cohort of the trial showed an 86.5% reduction in Gb3 inclusion after six months (n=4); this data represents an 89.6% reduction for males (n=3) and a 77.3% reduction for females (n=1).", "type": 1, "words": ["<tag1>", "On", "average,", "patients", "that", "participated", "in", "the", "0.2mg/kg", "cohort", "of", "the", "PRX-102", "phase", "I/II", "trial", "exhibited", "stability", "in", "kidney", "function", "with", "favorable", "trends", "shown,", "as", "measured", "by", "estimated", "Glomerular", "filtration", "rate", "(eGFR).", "<tag2>", "Patients", "in", "the", "1", "mg/kg", "dosing", "cohort", "of", "the", "trial", "showed", "an", "86.5%", "reduction", "in", "Gb3", "inclusion", "after", "six", "months", "(n=4);", "this", "data", "represents", "an", "89.6%", "reduction", "for", "males", "(n=3)", "and", "a", "77.3%", "reduction", "for", "females", "(n=1).", "<tag3>"], "wordsA": ["On", "average,", "patients", "that", "participated", "in", "the", "0.2mg/kg", "cohort", "of", "the", "PRX-102", "phase", "I/II", "trial", "exhibited", "stability", "in", "kidney", "function", "with", "favorable", "trends", "shown,", "as", "measured", "by", "estimated", "Glomerular", "filtration", "rate", "(eGFR)."], "wordsB": ["Patients", "in", "the", "1", "mg/kg", "dosing", "cohort", "of", "the", "trial", "showed", "an", "86.5%", "reduction", "in", "Gb3", "inclusion", "after", "six", "months", "(n=4);", "this", "data", "represents", "an", "89.6%", "reduction", "for", "males", "(n=3)", "and", "a", "77.3%", "reduction", "for", "females", "(n=1)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_17_item1_p83_s1", "idA": "1006281_16_item1_p76_s2", "sentA": "Throughout the study, continuous and durable reduction of up to 61.8% of plasma lyso-Gb3 levels from base line was observed in patients in the 0.2mg/kg cohort.", "sentB": "A mean reduction of approximately 60% in DNA content from baseline was observed, and a mean reduction of approximately 90% from baseline was observed for sputa visco-elasticity.", "type": 1, "words": ["<tag1>", "Throughout", "the", "study,", "continuous", "and", "durable", "reduction", "of", "up", "to", "61.8%", "of", "plasma", "lyso-Gb3", "levels", "from", "base", "line", "was", "observed", "in", "patients", "in", "the", "0.2mg/kg", "cohort.", "<tag2>", "A", "mean", "reduction", "of", "approximately", "60%", "in", "DNA", "content", "from", "baseline", "was", "observed,", "and", "a", "mean", "reduction", "of", "approximately", "90%", "from", "baseline", "was", "observed", "for", "sputa", "visco-elasticity.", "<tag3>"], "wordsA": ["Throughout", "the", "study,", "continuous", "and", "durable", "reduction", "of", "up", "to", "61.8%", "of", "plasma", "lyso-Gb3", "levels", "from", "base", "line", "was", "observed", "in", "patients", "in", "the", "0.2mg/kg", "cohort."], "wordsB": ["A", "mean", "reduction", "of", "approximately", "60%", "in", "DNA", "content", "from", "baseline", "was", "observed,", "and", "a", "mean", "reduction", "of", "approximately", "90%", "from", "baseline", "was", "observed", "for", "sputa", "visco-elasticity."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_17_item1_p73_s0", "idA": "1006281_16_item1_p80_s0", "sentA": "In the official FDA meeting minutes, the FDA noted that we reported interim analysis results from the phase I/II clinical trial of PRX-102 that preliminarily show a favorable trend in the severity and frequency of abdominal pain and frequency of diarrhea after six months of treatment with PRX-102.", "sentB": "In summary, in the phase I/II trial, PRX-102 was found to have a markedly extended circulatory half-life compared with other ERTs; it demonstrated a low incidence of treatment induced ADA with reversible and transient effect on pharmacokinetics; ADA response was transient and tolerization was observed; and ADA positivity had no observed impact on safety and efficacy.", "type": 1, "words": ["<tag1>", "In", "the", "official", "FDA", "meeting", "minutes,", "the", "FDA", "noted", "that", "we", "reported", "interim", "analysis", "results", "from", "the", "phase", "I/II", "clinical", "trial", "of", "PRX-102", "that", "preliminarily", "show", "a", "favorable", "trend", "in", "the", "severity", "and", "frequency", "of", "abdominal", "pain", "and", "frequency", "of", "diarrhea", "after", "six", "months", "of", "treatment", "with", "PRX-102.", "<tag2>", "In", "summary,", "in", "the", "phase", "I/II", "trial,", "PRX-102", "was", "found", "to", "have", "a", "markedly", "extended", "circulatory", "half-life", "compared", "with", "other", "ERTs;", "it", "demonstrated", "a", "low", "incidence", "of", "treatment", "induced", "ADA", "with", "reversible", "and", "transient", "effect", "on", "pharmacokinetics;", "ADA", "response", "was", "transient", "and", "tolerization", "was", "observed;", "and", "ADA", "positivity", "had", "no", "observed", "impact", "on", "safety", "and", "efficacy.", "<tag3>"], "wordsA": ["In", "the", "official", "FDA", "meeting", "minutes,", "the", "FDA", "noted", "that", "we", "reported", "interim", "analysis", "results", "from", "the", "phase", "I/II", "clinical", "trial", "of", "PRX-102", "that", "preliminarily", "show", "a", "favorable", "trend", "in", "the", "severity", "and", "frequency", "of", "abdominal", "pain", "and", "frequency", "of", "diarrhea", "after", "six", "months", "of", "treatment", "with", "PRX-102."], "wordsB": ["In", "summary,", "in", "the", "phase", "I/II", "trial,", "PRX-102", "was", "found", "to", "have", "a", "markedly", "extended", "circulatory", "half-life", "compared", "with", "other", "ERTs;", "it", "demonstrated", "a", "low", "incidence", "of", "treatment", "induced", "ADA", "with", "reversible", "and", "transient", "effect", "on", "pharmacokinetics;", "ADA", "response", "was", "transient", "and", "tolerization", "was", "observed;", "and", "ADA", "positivity", "had", "no", "observed", "impact", "on", "safety", "and", "efficacy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_17_item1_p80_s3", "idA": "1006281_16_item1_p89_s0", "sentA": "AIR DNase is the subject of a phase I clinical trial involving 18 healthy volunteers.", "sentB": "The main efficacy endpoint is the change of forced expiratory volume (FEV1) and forced vital capacity (FVC).", "type": 1, "words": ["<tag1>", "AIR", "DNase", "is", "the", "subject", "of", "a", "phase", "I", "clinical", "trial", "involving", "18", "healthy", "volunteers.", "<tag2>", "The", "main", "efficacy", "endpoint", "is", "the", "change", "of", "forced", "expiratory", "volume", "(FEV1)", "and", "forced", "vital", "capacity", "(FVC).", "<tag3>"], "wordsA": ["AIR", "DNase", "is", "the", "subject", "of", "a", "phase", "I", "clinical", "trial", "involving", "18", "healthy", "volunteers."], "wordsB": ["The", "main", "efficacy", "endpoint", "is", "the", "change", "of", "forced", "expiratory", "volume", "(FEV1)", "and", "forced", "vital", "capacity", "(FVC)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_17_item1_p63_s4", "idA": "1006281_16_item1_p99_s2", "sentA": "The initial term of the technology transfer is seven years.", "sentB": "The endpoints of the study are safety, mean annualized change (slope) in eGFR, pain, plasma lyso GB3, immunogenicity and Quality of Life.", "type": 1, "words": ["<tag1>", "The", "initial", "term", "of", "the", "technology", "transfer", "is", "seven", "years.", "<tag2>", "The", "endpoints", "of", "the", "study", "are", "safety,", "mean", "annualized", "change", "(slope)", "in", "eGFR,", "pain,", "plasma", "lyso", "GB3,", "immunogenicity", "and", "Quality", "of", "Life.", "<tag3>"], "wordsA": ["The", "initial", "term", "of", "the", "technology", "transfer", "is", "seven", "years."], "wordsB": ["The", "endpoints", "of", "the", "study", "are", "safety,", "mean", "annualized", "change", "(slope)", "in", "eGFR,", "pain,", "plasma", "lyso", "GB3,", "immunogenicity", "and", "Quality", "of", "Life."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_17_item1_p87_s0", "idA": "1006281_16_item1_p99_s2", "sentA": "The initial term of the technology transfer is seven years.", "sentB": "Some of the major treatments are antiTNF drugs, administered as subcutaneous injections or as intravenous infusions.", "type": 1, "words": ["<tag1>", "The", "initial", "term", "of", "the", "technology", "transfer", "is", "seven", "years.", "<tag2>", "Some", "of", "the", "major", "treatments", "are", "antiTNF", "drugs,", "administered", "as", "subcutaneous", "injections", "or", "as", "intravenous", "infusions.", "<tag3>"], "wordsA": ["The", "initial", "term", "of", "the", "technology", "transfer", "is", "seven", "years."], "wordsB": ["Some", "of", "the", "major", "treatments", "are", "antiTNF", "drugs,", "administered", "as", "subcutaneous", "injections", "or", "as", "intravenous", "infusions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_17_item1_p93_s4", "idA": "1006281_16_item1_p99_s2", "sentA": "The initial term of the technology transfer is seven years.", "sentB": "Key efficacy endpoints include relevant disease parameters of the drug, including Mayo score and rectal bleeding.", "type": 1, "words": ["<tag1>", "The", "initial", "term", "of", "the", "technology", "transfer", "is", "seven", "years.", "<tag2>", "Key", "efficacy", "endpoints", "include", "relevant", "disease", "parameters", "of", "the", "drug,", "including", "Mayo", "score", "and", "rectal", "bleeding.", "<tag3>"], "wordsA": ["The", "initial", "term", "of", "the", "technology", "transfer", "is", "seven", "years."], "wordsB": ["Key", "efficacy", "endpoints", "include", "relevant", "disease", "parameters", "of", "the", "drug,", "including", "Mayo", "score", "and", "rectal", "bleeding."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_17_item1_p94_s3", "idA": "1006281_16_item1_p99_s5", "sentA": "If Fiocruz fails to comply with certain of its purchase commitments under the agreement, we may terminate the agreement, and all of our rights to the technology will be returned.", "sentB": "The agreement contains certain purchase commitments by Fiocruz.", "type": 1, "words": ["<tag1>", "If", "Fiocruz", "fails", "to", "comply", "with", "certain", "of", "its", "purchase", "commitments", "under", "the", "agreement,", "we", "may", "terminate", "the", "agreement,", "and", "all", "of", "our", "rights", "to", "the", "technology", "will", "be", "returned.", "<tag2>", "The", "agreement", "contains", "certain", "purchase", "commitments", "by", "Fiocruz.", "<tag3>"], "wordsA": ["If", "Fiocruz", "fails", "to", "comply", "with", "certain", "of", "its", "purchase", "commitments", "under", "the", "agreement,", "we", "may", "terminate", "the", "agreement,", "and", "all", "of", "our", "rights", "to", "the", "technology", "will", "be", "returned."], "wordsB": ["The", "agreement", "contains", "certain", "purchase", "commitments", "by", "Fiocruz."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
